[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1009
1. Lin CK, Yu MH, Chu TW, Lai HC: Synchronous occurrence of primary neoplasms in the uterus with squamous cell carcinoma of the cervix and adenocarcinoma of the endometrium. Taiwan J Obstet Gynecol; 2006 Dec;45(4):336-9
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous occurrence of primary neoplasms in the uterus with squamous cell carcinoma of the cervix and adenocarcinoma of the endometrium.
  • OBJECTIVE: Synchronous primary malignant neoplasms of the uterus are uncommon.
  • Patients with synchronous cervical and endometrial cancers are even rarer.
  • We describe a case of cervical squamous cell carcinoma and endometrial endometrioid adenocarcinoma occurring simultaneously in a 47-year-old woman presenting with massive menstrual bleeding.
  • Magnetic resonance imaging revealed a mass over the cervical region and endometrial lesions in the uterine cavity.
  • Surgical exploration disclosed a cervical tumor and erosion of the endometrium.
  • The pathologic findings were compatible with synchronous occurrence of primary neoplasms in the uterus with squamous cell carcinoma of the cervix and adenocarcinoma of the endometrium.
  • It is practical to pay more attention to the differential diagnosis of primary and metastatic tumors.
  • The second primary cancer that occurs in an individual with endometrial cancer may offer an opportunity for early detection.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma, Squamous Cell / diagnosis. Neoplasms, Multiple Primary / diagnosis. Uterine Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Endometrial Neoplasms / diagnosis. Female. Humans. Lymphatic Metastasis / diagnosis. Magnetic Resonance Imaging. Middle Aged

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17175494.001).
  • [ISSN] 1875-6263
  • [Journal-full-title] Taiwanese journal of obstetrics & gynecology
  • [ISO-abbreviation] Taiwan J Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  •  go-up   go-down


2. Mhawech-Fauceglia P, Herrmann RF, Kesterson J, Izevbaye I, Lele S, Odunsi K: Prognostic factors in stages II/III/IV and stages III/IV endometrioid and serous adenocarcinoma of the endometrium. Eur J Surg Oncol; 2010 Dec;36(12):1195-201

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in stages II/III/IV and stages III/IV endometrioid and serous adenocarcinoma of the endometrium.
  • AIMS: To explore and to compare the outcome of patients diagnosed with stage II/III/IV and stage III/IV endometrioid adenocarcinoma (EAC) with their serous carcinoma (USC) counterparts.
  • Despite our limited sample size, we believe that our findings provide meaningful insights into the clinical study of endometrial cancer patients which in turn warrants further investigation.
  • [MeSH-major] Carcinoma, Endometrioid / secondary. Cystadenocarcinoma, Serous / secondary. Endometrial Neoplasms / pathology. Predictive Value of Tests

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • [CommentIn] Eur J Surg Oncol. 2011 Aug;37(8):734-5; author reply 736 [21680132.001]
  • [Cites] Am J Obstet Gynecol. 1992 Sep;167(3):857-8 [1326895.001]
  • [Cites] Gynecol Oncol. 1994 Sep;54(3):264-8 [8088602.001]
  • [Cites] Am J Obstet Gynecol. 1983 Jul 1;146(5):495-500 [6859175.001]
  • [Cites] Gynecol Oncol. 1991 Jan;40(1):55-65 [1989916.001]
  • [Cites] Br J Cancer. 2006 Mar 13;94(5):642-6 [16495918.001]
  • [Cites] Int J Gynecol Cancer. 2009 Jul;19(5):879-83 [19574777.001]
  • [Cites] Gynecol Oncol. 2000 Apr;77(1):55-65 [10739691.001]
  • [Cites] Gynecol Oncol. 2009 Nov;115(2):244-8 [19712966.001]
  • [Cites] Curr Oncol Rep. 2008 Nov;10(6):505-11 [18928665.001]
  • [Cites] Int J Gynecol Cancer. 2009 Nov;19(8):1364-9 [20009891.001]
  • [Cites] Cancer. 2004 Nov 15;101(10):2214-21 [15452833.001]
  • [Cites] Gynecol Oncol. 2005 Jun;97(3):755-63 [15913742.001]
  • [Cites] Int J Gynecol Cancer. 2006 May-Jun;16(3):972-8 [16803471.001]
  • [Cites] Cancer. 1987 Oct 15;60(8 Suppl):2035-41 [3652025.001]
  • [Cites] Int J Gynecol Cancer. 2006 Jul-Aug;16(4):1648-55 [16884379.001]
  • [Cites] Gynecol Oncol. 2009 Oct;115(1):142-53 [19592079.001]
  • [Cites] Gynecol Oncol. 1994 Feb;52(2):237-40 [8314145.001]
  • [Cites] Gynecol Oncol. 1997 Sep;66(3):411-6 [9299254.001]
  • [Cites] Am J Clin Pathol. 2008 Jun;129(6):912-7 [18480008.001]
  • [Cites] Anticancer Res. 2007 Mar-Apr;27(2):1213-7 [17465265.001]
  • [Cites] Am J Surg Pathol. 2007 Jul;31(7):979-87 [17592263.001]
  • [Cites] Int J Gynecol Cancer. 2009 Jan;19(1):134-40 [19258955.001]
  • [Cites] Gynecol Oncol. 2009 Nov;115(2):249-56 [19692115.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Sep 1;54(1):79-85 [12182977.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • (PMID = 20926229.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / T32 CA108456
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] England
  •  go-up   go-down


3. Nishimura Y, Watanabe J, Jobo T, Hattori M, Arai T, Kuramoto H: Cytologic scoring of endometrioid adenocarcinoma of the endometrium. Cancer; 2005 Feb 25;105(1):8-12
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytologic scoring of endometrioid adenocarcinoma of the endometrium.
  • BACKGROUND: Endometrial carcinoma is one of the most frequent malignancies in the female genital tract, and its incidence has been increasing in Japan.
  • The objective of this study was to evaluate the applicability and usefulness of cytologic scoring in assessing the morphologic differentiation of endometrioid adenocarcinomas of the endometrium using endometrial smears.
  • METHODS: Sixty-four endometrial cytologic samples of endometrioid adenocarcinomas of the endometrium were used in this study.
  • All patients underwent endometrial cytology before hysterectomy, and the diagnosis was confirmed by histologic examination of the extirpated uterus.
  • The best cut-off value for distinguishing histologic Grade 1 from the others was a cytologic score of 17, representing a sensitivity of 83% and a specificity of 81%.
  • For distinguishing histologic Grade 3 from the others, the best cut-off value was a cytologic score of 20, representing a sensitivity of 100% and a specificity of 83%.
  • CONCLUSIONS: The cytologic scoring system studied for endometrioid adenocarcinoma was useful for predicting histologic grade and tumor malignant potential.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2004 American Cancer Society
  • (PMID = 15597380.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  •  go-up   go-down


Advertisement
4. Wildemeersch D, Anderson E, Lambein K, Pauwels P, Dhont M: Successful treatment of early endometrial carcinoma by local delivery of levonorgestrel: a case report. Obstet Gynecol Int; 2010;2010:431950

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of early endometrial carcinoma by local delivery of levonorgestrel: a case report.
  • We describe a case of a 67-year-old Caucasian woman with an early, moderately-differentiated adenocarcinoma of the endometrium.
  • Examination after 24 months showed a very thin endometrium, indicating complete remission.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20981240.001).
  • [ISSN] 1687-9597
  • [Journal-full-title] Obstetrics and gynecology international
  • [ISO-abbreviation] Obstet Gynecol Int
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2963141
  •  go-up   go-down


5. Jayakrishnan K, Anupama R, Koshy A, Raju R: Endometrial carcinoma in a young subfertile woman with polycystic ovarian syndrome. J Hum Reprod Sci; 2010 Jan;3(1):38-41

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial carcinoma in a young subfertile woman with polycystic ovarian syndrome.
  • Adenocarcinoma of the endometrium is a morbid condition in women under 40 years of age with an incidence of 25%.
  • However, patients with anovulatory polycystic ovarian syndrome are at risk of developing endometrial carcinoma.
  • In young women with menstrual abnormalities and polycystic ovarian disease and/or infertility, an endometrial evaluation should be performed.
  • Carcinoma endometrium should be kept in mind while evaluating young women with polycystic ovary syndrome for abnormal uterine bleeding.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2008 Dec;111(3):579-82 [18395778.001]
  • [Cites] Fertil Steril. 2008 Mar;89(3):724.e1-3 [17570366.001]
  • [Cites] Semin Reprod Med. 2008 Jan;26(1):62-71 [18181084.001]
  • [Cites] J Clin Oncol. 2007 Jul 1;25(19):2798-803 [17602085.001]
  • [Cites] Int J Gynecol Cancer. 2005 Jul-Aug;15(4):657-62 [16014120.001]
  • [Cites] BJOG. 2005 Mar;112(3):317-20 [15713146.001]
  • [Cites] Gynecol Oncol. 2000 Oct;79(1):129-32 [11006045.001]
  • [Cites] Fertil Steril. 1996 Jun;65(6):1083-9 [8641477.001]
  • [Cites] Endocrinology. 1995 Jun;136(6):2531-7 [7750475.001]
  • [Cites] Endocr Rev. 1990 Aug;11(3):443-53 [2226350.001]
  • [Cites] Br J Cancer. 1988 Feb;57(2):205-12 [3358913.001]
  • [Cites] Lancet. 2003 May 24;361(9371):1810-2 [12781553.001]
  • [Cites] Lancet. 2002 Jul 20;360(9328):235 [12133671.001]
  • [Cites] Hum Reprod. 1997 Aug;12(8):1649-53 [9308787.001]
  • (PMID = 20607008.001).
  • [ISSN] 1998-4766
  • [Journal-full-title] Journal of human reproductive sciences
  • [ISO-abbreviation] J Hum Reprod Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2890909
  • [Keywords] NOTNLM ; Endometrial adenocarcinoma / infertility / polycystic ovaries
  •  go-up   go-down


6. O'Brien DJ, Flannelly G, Mooney EE, Foley M: Lymphovascular space involvement in early stage well-differentiated endometrial cancer is associated with increased mortality. BJOG; 2009 Jun;116(7):991-4
Genetic Alliance. consumer health - Endometrial cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphovascular space involvement in early stage well-differentiated endometrial cancer is associated with increased mortality.
  • OBJECTIVE: To study the relationship between lymphovascular space involvement (LVSI) in stage 1a or 1b well-differentiated endometrial cancer and survival.
  • DESIGN: Retrospective study consisting of a search of an oncology database to identify women with endometrial cancer between January 1990 and December 2004.
  • SAMPLE: Women who had well-differentiated stage 1a or 1b endometrial cancer.
  • METHODS: During the period 1990-2004, 226 patients with endometrial cancer were treated in the National Maternity Hospital, Dublin.
  • We looked at all patients who had well-differentiated endometrioid adenocarcinoma of the endometrium with invasion of <50% thickness of the myometrium.
  • MAIN OUTCOME MEASURES: Death from recurrence of endometrial cancer.
  • CONCLUSION: In patients with early stage well-differentiated adenocarcinoma of the endometrium, the presence of LVSI is associated with a high risk of death.
  • [MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Endometrial Neoplasms / mortality. Endometrial Neoplasms / pathology. Lymphatic Vessels / pathology. Neoplasm Recurrence, Local / mortality

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19522800.001).
  • [ISSN] 1471-0528
  • [Journal-full-title] BJOG : an international journal of obstetrics and gynaecology
  • [ISO-abbreviation] BJOG
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


7. Gates EJ, Hirschfield L, Matthews RP, Yap OW: Body mass index as a prognostic factor in endometrioid adenocarcinoma of the endometrium. J Natl Med Assoc; 2006 Nov;98(11):1814-22
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Body mass index as a prognostic factor in endometrioid adenocarcinoma of the endometrium.
  • OBJECTIVE: To determine if body mass index (BMI) influences tumor expression of HER-2/neu, estrogen and progesterone receptors (ER/PR), and survival in women with endometrial adenocarcinoma.
  • METHODS: Patients diagnosed between January 1992 and December 2001 with endometrioid adenocarcinoma of the uterus were identified.
  • CONCLUSION: In patients with endometrioid adenocarcinoma, low BMI is associated with high stage and tumor expression of HER-2/neu.
  • [MeSH-major] Body Mass Index. Carcinoma, Endometrioid / mortality. Carcinoma, Endometrioid / physiopathology. Endometrial Neoplasms / mortality. Endometrial Neoplasms / physiopathology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Obstet Gynecol. 1979 Sep;54(3):269-77 [471366.001]
  • [Cites] J Natl Cancer Inst. 1977 Oct;59(4):1055-60 [333120.001]
  • [Cites] Cancer Res. 1981 Mar;41(3):1140-7 [6936073.001]
  • [Cites] Gynecol Oncol. 2001 Nov;83(2):388-93 [11606102.001]
  • [Cites] JAMA. 1980 Nov 28;244(21):2419-22 [7431569.001]
  • [Cites] Nat Rev Cancer. 2006 May;6(5):360-8 [16633364.001]
  • [Cites] Int J Epidemiol. 2006 Feb;35(1):151-8 [16278243.001]
  • [Cites] Am J Epidemiol. 2005 May 15;161(10):939-47 [15870158.001]
  • [Cites] Cancer. 1949 Nov;2(6):964-71, illust [15395195.001]
  • [Cites] Int J Gynecol Pathol. 1999 Apr;18(2):138-43 [10202671.001]
  • [Cites] J Clin Pathol. 1998 Jan;51(1):25-9 [9577367.001]
  • [Cites] Cancer Res. 1997 Nov 15;57(22):5077-85 [9371506.001]
  • [Cites] Gynecol Oncol. 1997 Apr;65(1):138-42 [9103403.001]
  • [Cites] Cancer Lett. 1996 Jan 2;98(2):151-5 [8556702.001]
  • [Cites] Am J Obstet Gynecol. 1995 Dec;173(6):1829-34 [8610771.001]
  • [Cites] Cancer Res. 1995 Dec 1;55(23):5693-8 [7585656.001]
  • [Cites] Nutr Cancer. 1995;23(2):141-9 [7644383.001]
  • [Cites] Am J Obstet Gynecol. 1994 Nov;171(5):1193-8 [7977518.001]
  • [Cites] Cancer Res. 1994 Mar 15;54(6):1604-7 [8137266.001]
  • [Cites] Gynecol Oncol. 1993 Feb;48(2):196-202 [8428691.001]
  • [Cites] Cancer. 1982 Nov 15;50(10):2157-62 [7127255.001]
  • [Cites] Pathol Res Pract. 1982 Aug;174(3):237-56 [7145769.001]
  • [Cites] Gynecol Oncol. 1983 Feb;15(1):10-7 [6822361.001]
  • [Cites] Obstet Gynecol. 1984 Jul;64(1):1-11 [6738931.001]
  • [Cites] Cancer Treat Rep. 1985 Feb;69(2):237-8 [3971394.001]
  • [Cites] Cancer. 1985 Sep 15;56(6):1452-5 [4027879.001]
  • [Cites] Cancer Detect Prev. 1987;10(3-4):237-46 [3568022.001]
  • [Cites] Am J Obstet Gynecol. 1988 Apr;158(4):796-807 [2966586.001]
  • [Cites] Gynecol Oncol. 1990 Sep;38(3):364-6 [2227549.001]
  • [Cites] Rev Fr Gynecol Obstet. 1990 Oct;85(10):513-6 [2263829.001]
  • [Cites] Am J Obstet Gynecol. 1991 Jan;164(1 Pt 1):15-21 [1670908.001]
  • [Cites] Gynecol Oncol. 1992 Nov;47(2):179-85 [1361478.001]
  • (PMID = 17128692.001).
  • [ISSN] 1943-4693
  • [Journal-full-title] Journal of the National Medical Association
  • [ISO-abbreviation] J Natl Med Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, ErbB-2
  • [Other-IDs] NLM/ PMC2569783
  •  go-up   go-down


8. Orezzoli JP, Sioletic S, Olawaiye A, Oliva E, del Carmen MG: Stage II endometrioid adenocarcinoma of the endometrium: clinical implications of cervical stromal invasion. Gynecol Oncol; 2009 Jun;113(3):316-23
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage II endometrioid adenocarcinoma of the endometrium: clinical implications of cervical stromal invasion.
  • OBJECTIVES: Endometrioid adenocarcinoma of the endometrium (EEC) is the most common histologic type of endometrial cancer, with stage being the most critical prognostic factor.
  • C) >3 mm and < or =5 mm and D) >5 mm.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / pathology. Neoplasm Invasiveness. Neoplasm Staging
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Hysterectomy. Middle Aged. Prognosis. Retrospective Studies. Survival Analysis. Uterine Cervical Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19345400.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Snyder MJ, Bentley R, Robboy SJ: Transtubal spread of serous adenocarcinoma of the endometrium: an underrecognized mechanism of metastasis. Int J Gynecol Pathol; 2006 Apr;25(2):155-60
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transtubal spread of serous adenocarcinoma of the endometrium: an underrecognized mechanism of metastasis.
  • Most endometrial carcinomas metastasize by invading myometrial lymphatics and spreading to regional lymph nodes.
  • However, uterine serous carcinomas (USCs) metastasize frequently to peritoneal surfaces even when only minimally invasive.
  • This explains the phenomenon whereby patients with serous carcinomas confined to the endometrium and lacking LV invasion have widespread metastases to the peritoneum.
  • [MeSH-major] Adenocarcinoma, Scirrhous / pathology. Adenocarcinoma, Scirrhous / secondary. Endometrial Neoplasms / pathology. Fallopian Tube Neoplasms / secondary. Neoplasm Metastasis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16633065.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Takeuchi K, Kitazawa S, Hamanishi S, Inagaki M, Murata K: A case of alpha-fetoprotein-producing adenocarcinoma of the endometrium with a hepatoid component as a potential source for alpha-fetoprotein in a postmenopausal woman. Int J Gynecol Cancer; 2006 May-Jun;16(3):1442-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of alpha-fetoprotein-producing adenocarcinoma of the endometrium with a hepatoid component as a potential source for alpha-fetoprotein in a postmenopausal woman.
  • Although case reports of alpha-fetoprotein (AFP)-producing adenocarcinoma other than hepatocellular carcinoma have gradually increased in number, AFP-producing adenocarcinoma of the endometrium is very rare.
  • Radiologic imaging and endoscopy did not provide evidence of any primary carcinoma in the liver and gastrointestinal tract.
  • To investigate the unknown origin of high AFP, Pap smear of the endometrium followed by fractional curettage was performed and revealed adenocarcinoma of the endometrium.
  • Histologic study showed a mixture of major AFP-negative endometrioid adenocarcinoma and minor medullary proliferation of the AFP-positive hepatoid adenocarcinoma cells with eosinophilic cytoplasm and hyaline globules.
  • The possible existence of AFP-producing adenocarcinoma of the endometrium should be considered in a postmenopausal woman even if there is no vaginal bleeding, when AFP-producing tumor is clinically suspected and the imaging studies fail to confirm the diagnosis.
  • [MeSH-major] Carcinoma, Endometrioid / secretion. Carcinoma, Hepatocellular / secondary. Endometrial Neoplasms / secretion. alpha-Fetoproteins / secretion

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16803544.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / alpha-Fetoproteins
  • [Number-of-references] 10
  •  go-up   go-down


11. Morgan J, Sadler MA: Acute gastric outlet obstruction secondary to papillary serous adenocarcinoma of the endometrium with peritoneal psammomatous implants: a case report. Emerg Radiol; 2010 Jan;17(1):65-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute gastric outlet obstruction secondary to papillary serous adenocarcinoma of the endometrium with peritoneal psammomatous implants: a case report.
  • Endometrial carcinoma is the most common gynecologic cancer in the United States.
  • Uterine papillary serous carcinoma comprises approximately 5-10% of endometrial carcinomas.
  • This aggressive carcinoma typically occurs in older women, characteristically arising on atrophic endometrium.
  • We present a case of acute gastric outlet obstruction secondary to papillary serous adenocarcinoma of the endometrium with diffuse peritoneal psammomatous implants.
  • [MeSH-major] Cystadenocarcinoma, Papillary / complications. Cystadenocarcinoma, Serous / complications. Endometrial Neoplasms / complications. Gastric Outlet Obstruction / etiology
  • [MeSH-minor] Abdomen, Acute / diagnostic imaging. Aged. Contrast Media. Diagnosis, Differential. Female. Humans. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Gynecol Pathol. 1990;9(2):110-21 [2332269.001]
  • [Cites] Am J Clin Pathol. 1972 Mar;57(3):297-302 [4259707.001]
  • [Cites] AJR Am J Roentgenol. 2004 Jun;182(6):1534-6 [15150003.001]
  • [Cites] Am J Pathol. 1961 Oct;39:499-510 [13752576.001]
  • [Cites] Lab Invest. 1980 Sep;43(3):287-96 [7401638.001]
  • [Cites] Am J Surg Pathol. 1998 Jul;22(7):849-62 [9669347.001]
  • [Cites] Eur J Gynaecol Oncol. 1993;14(1):46-50 [8472732.001]
  • [Cites] Gynecol Oncol. 1983 Feb;15(1):10-7 [6822361.001]
  • [Cites] Am J Obstet Gynecol. 1971 Jan 1;109(1):113-8 [4321483.001]
  • [Cites] Radiology. 1986 Mar;158(3):649-52 [3945732.001]
  • [Cites] Cancer. 1972 May;29(5):1326-35 [5021621.001]
  • [Cites] Am J Surg Pathol. 1982 Mar;6(2):93-108 [7102898.001]
  • (PMID = 19132421.001).
  • [ISSN] 1438-1435
  • [Journal-full-title] Emergency radiology
  • [ISO-abbreviation] Emerg Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


12. Tretheway D, Gebhardt JG, Dogra VS, Schiffhauer LM: Metastatic versus primary oncocytic papillary adenocarcinoma of the endometrium: a report of a case and review of the literature. Int J Gynecol Pathol; 2009 May;28(3):256-61

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic versus primary oncocytic papillary adenocarcinoma of the endometrium: a report of a case and review of the literature.
  • We report a case of an oncocytic papillary adenocarcinoma of the endometrium in an 89-year-old female with vaginal bleeding.
  • Imaging studies revealed lesions in the uterus, kidneys, pancreas, gluteus, and an enlarged portacaval lymph node.
  • Diagnostic workup included an endometrial biopsy which showed malignant, oncocytic cells in a predominantly papillary pattern.
  • The cells were negative for cytokeratin 903, CAM 5.2, progesterone receptor, CD10, RCC Marker, CA-125, c-kit, and vimentin.
  • Consultation with experts in Gynecologic and Genitourinary pathology returned a diagnosis of "adenocarcinoma compatible with metastatic renal cell carcinoma"--an intriguing possibility worthy of further exploration.
  • To our knowledge, there are no reports in the literature of metastatic oncocytic papillary renal cell carcinoma to the endometrium.
  • The clinical and pathologic features of oncocytic papillary endometrial lesions, including primary and metastatic processes, are reviewed.
  • [MeSH-major] Adenocarcinoma, Papillary / pathology. Endometrial Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19620943.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 13
  •  go-up   go-down


13. Toyoda M, Satoh T, Takano K, Sato NO, Oki A, Tsunoda H, Yoshikawa H: Successful diagnosis of thromboembolism before surgery in a woman with clear cell adenocarcinoma of the endometrium. Int J Clin Oncol; 2005 Dec;10(6):444-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful diagnosis of thromboembolism before surgery in a woman with clear cell adenocarcinoma of the endometrium.
  • Patients with ovarian cancer with clear cell histology often have venous thromboembolism (VTE) even before surgery.
  • In view of the possible association between clear cell histology and VTE in endometrial cancer, we measured the plasma levels of thrombin-antithrombin III complex (TAT) and D-dimer (DD) in the preoperative examinations of a patient with clear cell adenocarcinoma of the endometrium.
  • Ultrasound Doppler examination and lung perfusion scintigraphy just before surgery revealed a thrombosis in the left popliteal vein and a pulmonary embolism.
  • [MeSH-major] Adenocarcinoma, Clear Cell / complications. Endometrial Neoplasms / complications. Thromboembolism / complications. Thromboembolism / diagnosis
  • [MeSH-minor] Aged. Antithrombin III. Female. Fibrin Fibrinogen Degradation Products / metabolism. Humans. Hysterectomy. Ovariectomy. Peptide Hydrolases / blood. Popliteal Vein. Preoperative Care. Pulmonary Embolism / blood. Pulmonary Embolism / complications. Pulmonary Embolism / diagnosis. Venous Thrombosis / blood. Venous Thrombosis / complications. Venous Thrombosis / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Gynecol Pathol. 2001 Jul;20(3):252-9 [11444201.001]
  • [Cites] Gynecol Oncol. 1996 Mar;60(3):412-7 [8774649.001]
  • [Cites] Thromb Res. 1998 Jul 15;91(2):101-4 [9722026.001]
  • [Cites] Cancer. 1996 Nov 15;78(10):2157-63 [8918409.001]
  • [Cites] Thromb Haemost. 1996 Jul;76(1):9-11 [8819243.001]
  • [Cites] Thromb Haemost. 1994 Jan;71(1):1-6 [8165626.001]
  • (PMID = 16369752.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Fibrin Fibrinogen Degradation Products; 0 / antithrombin III-protease complex; 0 / fibrin fragment D; 9000-94-6 / Antithrombin III; EC 3.4.- / Peptide Hydrolases
  •  go-up   go-down


14. Rasool N, Fader AN, Seamon L, Neubauer NL, Shahin FA, Alexander HA, Moore K, Moxley K, Secord AA, Kunos C, Rose PG, O'Malley DM: Stage I, grade 3 endometrioid adenocarcinoma of the endometrium: an analysis of clinical outcomes and patterns of recurrence. Gynecol Oncol; 2010 Jan;116(1):10-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage I, grade 3 endometrioid adenocarcinoma of the endometrium: an analysis of clinical outcomes and patterns of recurrence.
  • OBJECTIVE: To study patterns of recurrence and survival outcomes in patients with surgical stage I, grade 3 endometrioid adenocarcinoma of the endometrium (EA) treated with various treatment modalities.
  • Sixty-one patients (35%) had lymphovascular space invasion (LVSI) and a mean of 18.9 lymph nodes (LNs) was removed.
  • CONCLUSIONS: Patients with stage IB/IC, grade 3 endometrioid adenocarcinoma have a significant risk for extra-pelvic recurrence.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Carcinoma, Endometrioid / therapy. Endometrial Neoplasms / pathology. Endometrial Neoplasms / therapy. Neoplasm Recurrence, Local / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Gynecol Oncol. 2010 Jun;117(3):507; author reply 507-8 [20189231.001]
  • (PMID = 19875158.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


15. Pollock J: Letter to the editor in response to "Stage 1, grade 3 endometrioid adenocarcinoma of the endometrium: An analysis of clinical outcomes and patterns of recurrence". Gynecol Oncol; 2010 Jun;117(3):507; author reply 507-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Letter to the editor in response to "Stage 1, grade 3 endometrioid adenocarcinoma of the endometrium: An analysis of clinical outcomes and patterns of recurrence".
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Carcinoma, Endometrioid / therapy. Endometrial Neoplasms / pathology. Endometrial Neoplasms / therapy. Neoplasm Recurrence, Local / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Gynecol Oncol. 2010 Jan;116(1):10-4 [19875158.001]
  • (PMID = 20189231.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  •  go-up   go-down


16. Karateke A, Haliloglu B, Atay V, Gurbuz A, Kir G: A case of microglandular adenocarcinoma of the endometrium. Gynecol Oncol; 2005 Dec;99(3):778-81

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of microglandular adenocarcinoma of the endometrium.
  • BACKGROUND: Microglandular adenocarcinoma is a rare type of endometrium carcinoma and had some potential diagnostic problems with difficulties in discriminating from some malign and benign lesions of cervix.
  • CASE REPORT: A 70-year-old woman misdiagnosed as cervical adenocarcinoma was referred to our clinic, and the lesion was ultimately evaluated as microglandular adenocarcinoma in repeat of endometrial curettage specimen.
  • Postoperatively, histopathologic examination of specimen revealed grade 1 microglandular adenocarcinoma.
  • To our best knowledge, this is the twelfth case of uterine carcinoma simulating microglandular hyperplasia in the literature.
  • CONCLUSION: Because microglandular adenocarcinoma can be confused with benign lesions like microglandular hyperplasia and malignant lesions of cervix, we aim to discuss the clinical, demographic and immunohistochemical characteristics of the patients with microglandular adenocarcinoma useful in differential diagnosis.
  • [MeSH-major] Adenocarcinoma / diagnosis. Endometrial Neoplasms / diagnosis
  • [MeSH-minor] Aged. Diagnosis, Differential. Endometrial Hyperplasia / diagnosis. Endometrial Hyperplasia / metabolism. Endometrial Hyperplasia / pathology. Female. Humans. Immunohistochemistry. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / metabolism. Uterine Cervical Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16229880.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Arnaoutakis K, Morse AB, Ambika S, Wong G, Parameswaran R: Practice-based improvement (PBI) via web based tool (WBT) in multidisciplinary gynecologic oncology clinic (MGOC). J Clin Oncol; 2009 May 20;27(15_suppl):e17545

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Few studies document evaluation of risk of late side effects of cancer therapy.
  • Part 1 evaluation showed that 68 % pts had endometrial adenocarcinoma; 20% cervical cancer; 12% uterine sarcoma or carcinosarcoma.
  • No pts had complete fall risk evaluation, estimated dietary calcium (Ca)/vitamin D intake or documented adequacy of Ca or vit D intake.
  • Counseling for appropriate Ca/vitamin D intake was poor (4%/8%).
  • We have targeted areas for improvement for part 2: vit D level evaluation, assessment of and counseling for adequate of Ca/ vit D intake and WBE.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963762.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Kaur J, Dey P: Mean nuclear volume in complex atypical hyperplasia and adenocarcinoma of the endometrium. Anal Quant Cytol Histol; 2010 Oct;32(5):291-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mean nuclear volume in complex atypical hyperplasia and adenocarcinoma of the endometrium.
  • OBJECTIVE: To explore the possible role of mean nuclear volume (MNV) in differentiating complex atypical hyperplasia (CAH) from well-differentiated adenocarcinoma (WDAC) of the endometrium.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22043505.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Levakov SA, Zaĭrat'iants OV, Sidorova IS, Opalenov KV, Ali AG: [Detection rates of various serotypes of human papilloma virus in atypical glandular hyperplasia and adenocarcinoma of the endometrium and their immunomorphological features in virus-positive cases]. Arkh Patol; 2007 Mar-Apr;69(2):6-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Detection rates of various serotypes of human papilloma virus in atypical glandular hyperplasia and adenocarcinoma of the endometrium and their immunomorphological features in virus-positive cases].
  • They were detectable in 35.3 -52.9% of cases of atypical glandular hyperplasia, highly and moderately differentiated adenocarcinoma of the endometrium and only in 17.6% of cases of poorly differentiated adenocarcinomas.
  • The endometrium and tumors showed an increased significant proliferative activity (Ki-67 expression) and reduced expression of receptors to progesterone and, to a lesser degree, to estrogen in 47-83% of virus-positive cases.
  • [MeSH-major] Adenocarcinoma. Endometrial Hyperplasia. Endometrial Neoplasms. Papillomaviridae / isolation & purification. Papillomavirus Infections

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17642182.001).
  • [ISSN] 0004-1955
  • [Journal-full-title] Arkhiv patologii
  • [ISO-abbreviation] Arkh. Patol.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Ki-67 Antigen
  •  go-up   go-down


20. Faruqi SA, Harsch C, Saquib M, Noumoff J: Clonal Variation within an Adenocarcinoma of the Endometrium Cultured in Different Substrates and Media. J Assoc Genet Technol; 2009;35(1):5-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clonal Variation within an Adenocarcinoma of the Endometrium Cultured in Different Substrates and Media.
  • An adenocarcinoma of the endometrium was cultured separately in four different combinations of two substrates (normal tissue culture plastic and PrimariaTM) and two media (RPMI-1640 and serum free LHC-9).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19252255.001).
  • [ISSN] 1523-7834
  • [Journal-full-title] Journal of the Association of Genetic Technologists
  • [ISO-abbreviation] J Assoc Genet Technol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Marchesoni D, Driul L, Mozzanega B, Nardelli GB, Parenti A: Intraepithelial G3 adenocarcinoma of the endometrium after tamoxifen treatment. Arch Gynecol Obstet; 2005 Jan;271(1):62-5
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraepithelial G3 adenocarcinoma of the endometrium after tamoxifen treatment.
  • CASE REPORT: In this paper we describe a case of endometrial carcinoma observed in a post-menopausal patient who was treated with tamoxifen for 5 years after a mastectomy for cancer.
  • TREATMENT: She underwent hysteroscopy and a D and C.
  • A polypoid endometrium completely filled the uterine cavity and was carefully removed by curettage; histology showed a highly undifferentiated neoplasia with a component of serous adenocarcinoma, which was likely to originate from endometrial polyps.
  • OUTCOME: The patient underwent radical hysterectomy, but no residual tumor was found in the uterus or in the tubes, ovary, or pelvic nodes, in spite of its low differentiation grade and high potential aggressiveness, and even though the patient was already symptomatic.
  • [MeSH-major] Adenocarcinoma / chemically induced. Anticarcinogenic Agents / adverse effects. Antineoplastic Agents, Hormonal / adverse effects. Carcinoma in Situ / chemically induced. Endometrial Neoplasms / chemically induced. Tamoxifen / adverse effects
  • [MeSH-minor] Breast Neoplasms / drug therapy. Breast Neoplasms / surgery. Carcinoma, Ductal / drug therapy. Carcinoma, Ductal / surgery. Chemotherapy, Adjuvant. Dilatation and Curettage. Endometrium / drug effects. Endometrium / pathology. Female. Humans. Hysteroscopy. Mastectomy, Radical. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15290168.001).
  • [ISSN] 0932-0067
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


22. Klopp AH, Jhingran A, Ramondetta L, Lu K, Gershenson DM, Eifel PJ: Node-positive adenocarcinoma of the endometrium: outcome and patterns of recurrence with and without external beam irradiation. Gynecol Oncol; 2009 Oct;115(1):6-11
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Node-positive adenocarcinoma of the endometrium: outcome and patterns of recurrence with and without external beam irradiation.
  • OBJECTIVE: To evaluate treatment outcomes and patterns of recurrence in patients with node-positive (International Federation of Obstetrics and Gynecology stage IIIC) adenocarcinoma of the uterus without serous or clear cell differentiation.
  • METHODS: The records of 71 women who were treated for stage IIIC endometrial adenocarcinoma at our institution between 1984 and 2005 were reviewed.
  • Patients with stage IIIC endometrial adenocarcinoma who underwent surgical staging followed by external beam irradiation had a high rate of cure.
  • Relapses in patients treated with EBRT primarily occurred in patients with grade 3 cancer who may be most likely to benefit from combined-chemoradiation treatment.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Endometrial Neoplasms / radiotherapy

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19632709.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


23. Macdonald OK, Sause WT, Lee RJ, Dodson MK, Zempolich K, Gaffney DK: Does oncologic specialization influence outcomes following surgery in early stage adenocarcinoma of the endometrium? Gynecol Oncol; 2005 Dec;99(3):730-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does oncologic specialization influence outcomes following surgery in early stage adenocarcinoma of the endometrium?
  • OBJECTIVE: To evaluate treatment outcomes in women with early-stage endometrial cancer (FIGO IA, IB, IC, or IIA) surgically managed by a general gynecologist (GYN) or a gynecologic oncologist (GYO).
  • [MeSH-major] Adenocarcinoma / surgery. Endometrial Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16139348.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Cozad SC: Stage II adenocarcinoma of the endometrium: adjuvant radiotherapy and recurrence patterns. Int J Radiat Oncol Biol Phys; 2008 May 1;71(1):205-12

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage II adenocarcinoma of the endometrium: adjuvant radiotherapy and recurrence patterns.
  • PURPOSE: Review patterns of recurrence for Stage II endometrial cancer in a community practice.
  • METHODS AND MATERIALS: A retrospective review of patients with endometrial cancer diagnosed between 1985-2002.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Endometrial Neoplasms / radiotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18164851.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Geisler JP, Linnemeier GC, Manahan KJ: Pelvic and para-aortic lymphadenectomy in patients with endometrioid adenocarcinoma of the endometrium. Int J Gynaecol Obstet; 2007 Jul;98(1):39-43

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pelvic and para-aortic lymphadenectomy in patients with endometrioid adenocarcinoma of the endometrium.
  • BACKGROUND: The purpose is to determine the rate of lymph node metastases in women with endometrioid adenocarcinoma of the endometrium (EAE) undergoing systematic lymphadenectomy.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology. Lymph Node Excision. Lymphatic Metastasis / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17490668.001).
  • [ISSN] 0020-7292
  • [Journal-full-title] International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
  • [ISO-abbreviation] Int J Gynaecol Obstet
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Arai T, Watanabe J, Kawaguchi M, Kamata Y, Nishimura Y, Jobo T, Kuramoto H: Clear cell adenocarcinoma of the endometrium is a biologically distinct entity from endometrioid adenocarcinoma. Int J Gynecol Cancer; 2006 Jan-Feb;16(1):391-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell adenocarcinoma of the endometrium is a biologically distinct entity from endometrioid adenocarcinoma.
  • Clear cell adenocarcinoma (CCA) of the endometrium has a poor prognosis, although the biologic features of this rare tumor are not clear.
  • Thirteen cases of CCA were compared with cases of endometrioid adenocarcinoma (EMA) of the endometrium.
  • Immunohistochemical staining for p53; Ki-67; cyclins A, D1, and E; E-cadherin; progesterone receptor (PR)-A and PR-B; P-glycoprotein; MLH1; and MSH2 was performed.
  • No CCAs were positive for PR-A and PR-B.
  • The mechanism of cell-cycle regulation in endometrial CCA is different from that in EMA and may influence its malignant potential.
  • Endometrial CCA is a distinct entity from EMA.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Biomarkers, Tumor / analysis. Cadherins / analysis. Carcinoma, Endometrioid / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Biopsy, Needle. Cohort Studies. Cyclin A / analysis. Cyclin D1 / analysis. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Ki-67 Antigen / analysis. Middle Aged. Neoplasm Staging. Retrospective Studies. Sensitivity and Specificity. Tumor Suppressor Protein p53

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16445664.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / Cyclin A; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53; 136601-57-5 / Cyclin D1
  •  go-up   go-down


27. Desrosiers L, Fadare O, Xiao ZF, Dresser K, Wang SA: Lymphovascular space invasion does not predict vaginal relapses in stage I endometrioid adenocarcinoma of the endometrium. Ann Diagn Pathol; 2008 Apr;12(2):112-7
MedlinePlus Health Information. consumer health - Vaginal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphovascular space invasion does not predict vaginal relapses in stage I endometrioid adenocarcinoma of the endometrium.
  • This study was conducted to determine whether, in a pure population of patients with International Federation of Gynecology and Obstetrics stage I endometrioid endometrial (S1EE) carcinoma that is confined to the uterus and without lymph node metastases, the presence of lymphovascular space invasion (LVSI) is positively associated with vaginal relapses.
  • [MeSH-major] Carcinoma, Endometrioid / secondary. Endometrial Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Neoplasms, Second Primary / pathology. Vaginal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18325471.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Chebib I, Chu P, Duggan MA, DiFrancesco LM: Primary signet-ring cell adenocarcinoma of the endometrium: case report and review of the literature. Int J Gynecol Pathol; 2010 May;29(3):269-72
MedlinePlus Health Information. consumer health - Deep Vein Thrombosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary signet-ring cell adenocarcinoma of the endometrium: case report and review of the literature.
  • Endometrial adenocarcinoma presenting with deep venous thrombosis is an exceptional event more typical of extra-mullerian primary tumors.
  • In addition, primary endometrial adenocarcinoma with signet-ring cell features has been reported only once.
  • This study describes a case of primary endometrial carcinoma with prominent signet-ring cell features that presented in an unusual manner: with bilateral deep vein thromboses and splenic metastases.
  • [MeSH-major] Carcinoma, Signet Ring Cell / pathology. Endometrial Neoplasms / pathology. Splenic Neoplasms / secondary. Venous Thrombosis / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20407328.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Rauh-Hain JA, Costaaggini I, Olawaiye AB, Growdon WB, Horowitz NS, del Carmen MG: A comparison of outcome in patients with stage 1 clear cell and grade 3 endometrioid adenocarcinoma of the endometrium with and without adjuvant therapy. Eur J Gynaecol Oncol; 2010;31(3):284-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A comparison of outcome in patients with stage 1 clear cell and grade 3 endometrioid adenocarcinoma of the endometrium with and without adjuvant therapy.
  • OBJECTIVE: To determine the outcomes in patients with Stage I uterine clear cell carcinoma (UCCC) treated with and without adjuvant therapy, and to compare the outcomes in these patients to that of matched controls, patients with Stage I, grade 3, endometrioid adenocarcinoma of the endometrium (EC).
  • Cases (UCCC) were matched by age, stage, adjuvant therapy, and year of diagnosis to controls consisting of patients with grade 3 EC.
  • These data question the benefit of radiation therapy in UCCC patients with disease confined to the uterus.
  • [MeSH-major] Adenocarcinoma, Clear Cell / therapy. Carcinoma, Endometrioid / therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Case-Control Studies. Chemotherapy, Adjuvant. Endometrial Neoplasms. Female. Humans. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21077469.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


30. Qian J, Weber D, Cochran R, Hossain D, Bostwick DG: Detection of chromosomal anomalies in uterine endometrial carcinoma using fluorescence in situ hybridization (UteroFISH). J Clin Oncol; 2009 May 20;27(15_suppl):5533

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of chromosomal anomalies in uterine endometrial carcinoma using fluorescence in situ hybridization (UteroFISH).
  • : 5533 Background: Endometrial cancer is the most common pelvic gynecological malignancy.
  • The diagnosis of well-differentiated endometrial adenocarcinoma, atypical hyperplasia, and marked hyperplasia is often challenging.
  • We sought to investigate the utility of chromosomal anomalies for the detection of uterine endometrial carcinoma using multitarget fluorescence in situ hybridization (FISH).
  • METHODS: Samples were collected by endometrial brush and processed by liquid-based thin-layer cytological preparation protocol.
  • For study, we collected cytology slides from consecutive cases to include 50 benign, 50 hyperplasia without atypia, 50 atypical hyperplasia, and 50 endometrial cancers.
  • The FISH signals were enumerated in 100 cells per case, and the chromosomal anomalies were correlated with pathologic findings, including histologic diagnoses on endometrial tissue samples.
  • RESULTS: Numeric chromosomal anomalies were found in 0% (0/50) of benign, 20% (10/50) of hyperplasia, 76% of atypical hyperplasia (38/50), and 86% (43/50) of carcinoma specimens.
  • The mean percentage of cells with chromosomal changes was 54% in cancer specimens, significantly higher than that in hyperplasia without atypia (13%, p< 0.0001) and atypical hyperplasia (34%, p< 0.0001).
  • FISH anomalies had an overall sensitivity of 81% and specificity of 90% for the detection of atypical hyperplasia and/or endometrial carcinoma.
  • There was no association with grade of endometrial carcinoma.
  • CONCLUSIONS: Multi-target UteroFISH appeared to be useful for the differential diagnosis of reactive hyperplasia, atypical hyperplasia, and endometrial adenocarcinoma, with a high level of sensitivity and specificity.
  • Endometrial hyperplasia with FISH-detected chromosomal anomalies may require close clinical follow-up.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962491.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Espino-Strebel E, Luna JT: Correlation between preoperative serum CA 125 and surgicopathologic prognostic factors in endometrial cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e16524

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation between preoperative serum CA 125 and surgicopathologic prognostic factors in endometrial cancer.
  • : e16524 Background: Poor prognostic factors dictating the need for extended surgical staging among endometrial cancer patients can be accurately determined only after laparotomy.
  • This prospective study was conducted to determine the correlation between preoperative serum CA125 and surgicopathologic prognostic factors in endometrial cancer.
  • METHODS: Endometrial cancer patients diagnosed from October 2006 to July 2008 who were eligible for primary surgical treatment were included.
  • RESULTS: Ninety patients with endometrioid endometrial adenocarcinoma were included.
  • It is recommended that serum CA125 determination be part of the preoperative work-up of endometrial cancer patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960797.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Bewtra C, Xie QM, Hunter WJ, Jurgensen W: Ichthyosis uteri: a case report and review of the literature. Arch Pathol Lab Med; 2005 May;129(5):e124-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Squamous metaplasia of endometrium is mostly manifested by morules or nodules of benign nonkeratinizing squamous cells intimately mixed with benign or malignant endometrial glands.
  • It has been described with low-grade adenocarcinoma of the endometrium, as well as with various benign conditions, including hyperplasia, chronic endometritis, and endometrial polyps.
  • To our knowledge, we describe the first case of extensive benign squamous keratinization with underlying endometrial adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology. Ichthyosis / diagnosis. Uterus / pathology

  • Genetic Alliance. consumer health - Ichthyosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15859657.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 68238-35-7 / Keratins
  •  go-up   go-down


33. Mittal K: Distinguishing mucinous adenocarcinoma of the endometrium from benign endocervical epithelium. Int J Gynecol Pathol; 2009 Sep;28(5):479
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distinguishing mucinous adenocarcinoma of the endometrium from benign endocervical epithelium.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Biomarkers, Tumor / analysis. Endometrial Hyperplasia / pathology. Endometrial Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Gynecol Pathol. 2010 Jul;29(4):402-3 [20567157.001]
  • [CommentOn] Int J Gynecol Pathol. 2008 Oct;27(4):547-54 [18753965.001]
  • (PMID = 19696620.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


34. Brown L: Pathology of uterine malignancies. Clin Oncol (R Coll Radiol); 2008 Aug;20(6):433-47
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathology of uterine malignancies.
  • This overview covers epithelial, stromal and mesenchymal malignancies of the body of the uterus, excluding the cervix.
  • The distinction of type I and type II endometrial adenocarcinoma with the morphological variants of this tumour is discussed and some molecular aspects are explored.
  • The concept of carcinosarcoma representing a metaplastic adenocarcinoma of the endometrium that behaves more like a carcinoma than a sarcoma is explained.
  • The concept of stromal sarcoma and high-grade uterine sarcoma is described and an outline of malignant smooth muscle tumours of the uterus includes a description of smooth muscle tumours of uncertain malignant potential and worrying benign smooth muscle lesions.
  • [MeSH-major] Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Endometrial Stromal Tumors / pathology. Female. Humans. Leiomyosarcoma / pathology. Mesoderm / pathology. Neoplasms, Glandular and Epithelial / pathology. Sarcoma / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18499412.001).
  • [ISSN] 0936-6555
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 233
  •  go-up   go-down


35. Cannon GM, Geye H, Terakedis BE, Kushner DM, Connor JP, Hartenbach EM, Bradley KA: Outcomes following surgery and adjuvant radiation in stage II endometrial adenocarcinoma. Gynecol Oncol; 2009 May;113(2):176-80
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes following surgery and adjuvant radiation in stage II endometrial adenocarcinoma.
  • PURPOSE: To evaluate locoregional control, disease free survival, and overall survival in patients treated with surgery and adjuvant radiation for stage II adenocarcinoma of the endometrium.
  • MATERIALS AND METHODS: All patients receiving adjuvant radiation at the University of Wisconsin following surgery for FIGO stage II adenocarcinoma of the endometrium between January 1991 and December 2006 were retrospectively reviewed.
  • RESULTS: Between January 1991 and December 2006, 71 patients with FIGO stage II adenocarcinoma of the endometrium (23 stage IIA, 48 stage IIB) received adjuvant radiation at the University of Wisconsin.
  • DISCUSSION: Local recurrence rates remain low after surgery and adjuvant radiation therapy for stage II endometrial cancer using a combination of VB and EXT tailored to the surgical and pathologic features.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Endometrial Neoplasms / radiotherapy. Endometrial Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19217147.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Topuz S, Kalelioğlu I, Iyibozkurt C, Ergun B: Conservative management of a patient with endometrial carcinoma desiring fertility: how to inform? Eur J Gynaecol Oncol; 2008;29(6):661-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conservative management of a patient with endometrial carcinoma desiring fertility: how to inform?
  • Conservative management of patients with endometrial cancer who desire fertility is becoming widespread in certain circumstances.
  • A 36-year-old women desiring fertility with early-stage endometroid type adenocarcinoma of the endometrium was treated with 160 mg/d megestrol acetate for six months.
  • After confirmation of a normal endometrial biopsy she became pregnant spontaneously.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Carcinoma, Endometrioid / drug therapy. Endometrial Neoplasms / drug therapy. Megestrol Acetate / therapeutic use. Patient Participation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19115702.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; TJ2M0FR8ES / Megestrol Acetate
  •  go-up   go-down


37. Junaid I, Paz R, Salihu HM, Sharma PP, Aliyu ZY: Pseudo-Meig's syndrome with multiple synchronous benign and malignant pelvic tumors. Arch Gynecol Obstet; 2006 Feb;273(5):315-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pseudo-Meig's syndrome with multiple synchronous benign and malignant pelvic tumors.
  • BACKGROUND: Meig's and Pseudo-Meig's syndromes have been reported in association with several malignancies but the concomitant existence of multiple synchronous benign and malignant tumors in association with Pseudo-Meigs' syndrome has not been reported in the published literature.
  • CASE: A 55-year old African American woman presented with mild asthma exercebation, right ovarian mass, hydrothorax and elevated CA-125 levels.
  • Histological examination confirmed a right ovarian carcinoid tumor embedded within a mature cystic teratoma while the left ovary, fallopian tube and the uterus contained a poorly differentiated adenocarcinoma of the endometrium.
  • CONCLUSION: This is the first case report of Pseudo-Meig's syndrome in association with ovarian carcinoid tumor and multiple synchronous benign and malignant pelvic tumors.
  • [MeSH-minor] Adenocarcinoma / complications. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Asthma / complications. CA-125 Antigen / blood. Carcinoid Tumor / complications. Carcinoid Tumor / pathology. Carcinoid Tumor / surgery. Endometrial Neoplasms / complications. Endometrial Neoplasms / pathology. Endometrial Neoplasms / surgery. Fallopian Tube Neoplasms / complications. Fallopian Tube Neoplasms / pathology. Fallopian Tube Neoplasms / surgery. Female. Humans. Hydrothorax / complications. Middle Aged. Ovarian Neoplasms / complications. Ovarian Neoplasms / pathology. Ovarian Neoplasms / surgery. Teratoma / complications. Teratoma / pathology. Teratoma / surgery. Uterine Neoplasms / complications. Uterine Neoplasms / pathology. Uterine Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16136360.001).
  • [ISSN] 0932-0067
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / CA-125 Antigen
  •  go-up   go-down


38. Vilos GA, Ettler HC, Edris F, Hollett-Caines J, Abu-Rafea B: Endometrioid adenocarcinoma treated by hysteroscopic endomyometrial resection. J Minim Invasive Gynecol; 2007 Jan-Feb;14(1):119-22

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrioid adenocarcinoma treated by hysteroscopic endomyometrial resection.
  • A 53-year-old multiparous woman, with no identifiable risk factor for endometrial cancer, presented with menorrhagia.
  • Office endometrial biopsy indicated well-differentiated villoglandular adenocarcinoma of the endometrium.
  • We propose that skillful resectoscopic surgery, under specific circumstance, may be an appropriate alternative treatment to hysterectomy for some early uterine malignancies.
  • [MeSH-major] Carcinoma, Endometrioid / surgery. Endometrial Hyperplasia / pathology. Endometrial Neoplasms / surgery. Hysteroscopy / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17218243.001).
  • [ISSN] 1553-4650
  • [Journal-full-title] Journal of minimally invasive gynecology
  • [ISO-abbreviation] J Minim Invasive Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Smith DC, Macdonald OK, Lee CM, Gaffney DK: Survival impact of lymph node dissection in endometrial adenocarcinoma: a surveillance, epidemiology, and end results analysis. Int J Gynecol Cancer; 2008 Mar-Apr;18(2):255-61

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival impact of lymph node dissection in endometrial adenocarcinoma: a surveillance, epidemiology, and end results analysis.
  • The therapeutic benefit of lymph node dissection (LND) in women with endometrial cancer remains controversial.
  • Data were obtained from the Surveillance, Epidemiology, and End Results program of the US National Cancer Institute for the years 1988-2003.
  • Women with adenocarcinoma of the endometrium who underwent surgery as primary management of their disease were eligible.
  • On multivariate analysis, presence of LND was associated with overall and uterine-specific survival benefits with hazard ratios (HR) of 0.81 (P < 0.0001) and 0.78 (P < 0.0001) and removal of greater than 11 lymph nodes (LN) associated with a HR of 0.74 (P < 0.0001) and 0.69 (P < 0.0001), respectively.
  • Further multivariate analyses demonstrated greater than 11 LN to associate with all other cause-specific and cardiac-specific survival benefits, with HR of 0.77 (P < 0.0001) and 0.82 (P = 0.0062), respectively.
  • We conclude that the presence of LND and increased number of nodes dissected predicted for improved overall and uterine-specific survival in women with adenocarcinoma of the endometrium.
  • [MeSH-major] Endometrial Neoplasms / mortality. Lymph Node Excision / mortality
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Aged. Female. Humans. Middle Aged. SEER Program. Survival Analysis. United States / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17624991.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Minaguchi T, Nakagawa S, Takazawa Y, Nei T, Horie K, Fujiwara T, Osuga Y, Yasugi T, Kugu K, Yano T, Yoshikawa H, Taketani Y: Combined phospho-Akt and PTEN expressions associated with post-treatment hysterectomy after conservative progestin therapy in complex atypical hyperplasia and stage Ia, G1 adenocarcinoma of the endometrium. Cancer Lett; 2007 Apr 8;248(1):112-22
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined phospho-Akt and PTEN expressions associated with post-treatment hysterectomy after conservative progestin therapy in complex atypical hyperplasia and stage Ia, G1 adenocarcinoma of the endometrium.
  • Young patients with complex atypical hyperplasia (CAH) or stage Ia, G1 adenocarcinoma (IaG1) of the endometrium, who desire to preserve fertility, can select the conservative therapy by oral progestin, medroxyprogesterone acetate (MPA).
  • [MeSH-major] Adenocarcinoma / therapy. Endometrial Hyperplasia / therapy. Endometrial Neoplasms / therapy. Medroxyprogesterone Acetate / therapeutic use. PTEN Phosphohydrolase / metabolism. Proto-Oncogene Proteins c-akt / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16919866.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Contraceptive Agents, Female; 0 / Progestins; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 0 / Tumor Suppressor Protein p53; C2QI4IOI2G / Medroxyprogesterone Acetate; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


41. Castilho MS, Jacinto AA, Viani GA, Campana A, Carvalho J, Ferrigno R, Novaes PE, Fogaroli RC, Salvajoli JV: Intensity Modulated Radiotherapy (IMRT) in the postoperative treatment of an adenocarcinoma of the endometrium complicated by a pelvic kidney. Radiat Oncol; 2006;1:44

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensity Modulated Radiotherapy (IMRT) in the postoperative treatment of an adenocarcinoma of the endometrium complicated by a pelvic kidney.
  • BACKGROUND: Pelvic Radiotherapy (RT) as a postoperative treatment for endometrial cancer improves local regional control.
  • CASE: We report on a 50 year-old patient with a serous-papiliferous adenocarcinoma of the uterus who was submitted to surgical treatment without lymph node sampling followed by Brachytherapy, and Chemotherapy.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Endometrial Neoplasms / radiotherapy. Endometrial Neoplasms / surgery. Radiotherapy, Intensity-Modulated / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Transplantation. 2000 Sep 15;70(5):844-6 [11003368.001]
  • [Cites] Int J Gynaecol Obstet. 2000 Aug;70(2):209-62 [11041682.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Nov 15;57(4):1004-9 [14575831.001]
  • [Cites] Gynecol Oncol. 2004 Jan;92(1):376-9 [14751190.001]
  • [Cites] J Urol. 1980 May;123(5):766-7 [7420573.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Oct;19(4):977-83 [1976615.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 May 15;21(1):109-22 [2032882.001]
  • [Cites] Int J Gynaecol Obstet. 1993 Aug;42(2):174-6 [7901069.001]
  • [Cites] Transplantation. 1994 Aug 27;58(4):520-2 [8073523.001]
  • [Cites] Gynecol Oncol. 1995 Oct;59(1):151-5 [7557603.001]
  • [Cites] J Surg Oncol. 1996 Sep;63(1):57-60 [8841468.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Nov 1;63(3):834-8 [15927414.001]
  • [Cites] Radiother Oncol. 2005 Oct;77(1):11-7 [16024116.001]
  • (PMID = 17116263.001).
  • [ISSN] 1748-717X
  • [Journal-full-title] Radiation oncology (London, England)
  • [ISO-abbreviation] Radiat Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1660561
  • [General-notes] NLM/ Original DateCompleted: 20070809
  •  go-up   go-down


42. Talvensaari-Mattila A, Santala M, Soini Y, Turpeenniemi-Hujanen T: Prognostic value of matrix metalloproteinase-2 (MMP-2) expression in endometrial endometrioid adenocarcinoma. Anticancer Res; 2005 Nov-Dec;25(6B):4101-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of matrix metalloproteinase-2 (MMP-2) expression in endometrial endometrioid adenocarcinoma.
  • Matrix metalloproteinase-2 (MMP-2), a member of the zinc-dependent metalloproteinase gene family, plays an important role in cancer invasion and metastasis.
  • The current study aimed to evaluate whether the expression of MMP-2 is associated with survival in patients with endometrial endometrioid adenocarcinoma.
  • The MMP-2 immunoreactive protein was evaluated from endometrioid adenocarcinoma of the endometrium in 112 patients treated at Oulu University Hospital, Finland.
  • These data suggest that MMP-2 immunostaining negativity might be linked with a favourable prognosis in endometrial endometrioid adenocarcinoma.
  • [MeSH-major] Carcinoma, Endometrioid / enzymology. Endometrial Neoplasms / enzymology. Matrix Metalloproteinase 2 / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16309203.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] EC 3.4.24.24 / Matrix Metalloproteinase 2
  •  go-up   go-down


43. Park JK, Lee JI, Kim DC, Jo HC, Shin JK, Lee SA, Lee JH, Paik WY: Endometrial carcinoma in a patient having 45,X Turner syndrome with gonadal mosaicism. J Obstet Gynaecol Res; 2008 Aug;34(4 Pt 2):745-8
MedlinePlus Health Information. consumer health - Turner Syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial carcinoma in a patient having 45,X Turner syndrome with gonadal mosaicism.
  • Only three cases of endometrial carcinoma in women with possibly pure 45,X Turner syndrome without previous unopposed estrogen therapy have been reported.
  • A 46-year-old single nulligravid woman with Turner syndrome phenotype, spontaneous menstruation, and well-differentiated adenocarcinoma of the endometrium was diagnosed as having the 45,X karyotype from peripheral blood, skin, buccal cells, and endometrium, which was confirmed using fluorescence in situ hybridization (FISH).
  • Gonadal mosaicism may help to interpret spontaneous menstruation and endometrial carcinoma in possibly pure 45,X Turner syndrome.
  • [MeSH-major] Adenocarcinoma / complications. Endometrial Neoplasms / complications. Mosaicism. Ovary / pathology. Turner Syndrome / complications. Uterus / pathology

  • Genetic Alliance. consumer health - Turner syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18840195.001).
  • [ISSN] 1341-8076
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


44. Ivanov S: [Clinicopathological analysis in cases with glandular and atypical glandular hyperplasia treated with gestagens]. Akush Ginekol (Sofiia); 2005;44(4):18-20

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Many of the cases with endometrial adenocarcinoma of the endometrium are proceeded of glandular and atypical glandular hyperplasia with different risk of progression to neoplasia.
  • Two hundred and eighty cases with glandular and atypical glandular hyperplasia were examined in order to assess the risk of their progression into endometrial cancer.
  • The hyperplasias were evaluated separately for their likelihood of progression to cancer in patients treated and not treated with progestogen therapy.
  • 4% of the cases with glandular hyperplasia progressed into cancer and in 13% into atypical grandular hyperplasia.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Hyperplasia / pathology. Endometrial Neoplasms / pathology. Endometrium / pathology. Progestins / therapeutic use
  • [MeSH-minor] Dilatation and Curettage. Disease Progression. Female. Humans. Risk Assessment. Uterine Hemorrhage / complications. Uterine Hemorrhage / epidemiology. Uterine Hemorrhage / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16028373.001).
  • [ISSN] 0324-0959
  • [Journal-full-title] Akusherstvo i ginekologii︠a︡
  • [ISO-abbreviation] Akush Ginekol (Sofiia)
  • [Language] bul
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Bulgaria
  • [Chemical-registry-number] 0 / Progestins
  •  go-up   go-down


45. Oaknin A, Barretina MP, Morilla I: Muscle metastasis of low-grade endometrial carcinoma seven years after diagnosis: a case report. Eur J Gynaecol Oncol; 2010;31(1):114-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Muscle metastasis of low-grade endometrial carcinoma seven years after diagnosis: a case report.
  • BACKGROUND: Early-stage low-grade endometrial carcinoma has an excellent prognosis.
  • CASE: A 69-year-old woman underwent surgery for FIGO Stage IA, grade 1 endometrioid adenocarcinoma of the endometrium.
  • She died eight months after diagnosis of the bone and muscle metastases.
  • CONCLUSION: Low-risk endometrial carcinoma can behave like a high-risk group.
  • Furthermore, this report describes, to our knowledge, the first case of endometrial carcinoma muscle metastasis.
  • [MeSH-major] Carcinoma, Endometrioid / secondary. Endometrial Neoplasms / pathology. Muscle Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20349796.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


46. Henson DE, Schwartz AM, Tilara A, Grimley PM, Anderson WF: Population-based analysis of pathologic data: a new approach to the investigation of uterine endometrial and ovarian endometrioid carcinomas. Arch Pathol Lab Med; 2007 Sep;131(9):1337-42
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Population-based analysis of pathologic data: a new approach to the investigation of uterine endometrial and ovarian endometrioid carcinomas.
  • CONTEXT: Population-based analysis of the histopathology of endometrioid adenocarcinoma of the endometrium and ovary combined with epidemiologic techniques offer a new approach to exploring the relationship of tumors that share a similar range of morphologic phenotypes.
  • Specifically, to test and compare whether the etiology/pathogenesis of ovarian endometrioid cancer is as dependent upon the reproductive environment as uterine endometrial carcinoma.
  • DESIGN: Graphic plots of the epidemiologic patterns were analyzed relating to incidence and age-specific rates of ovarian and uterine endometrioid carcinomas.
  • RESULTS: At all ages, uterine endometrioid carcinomas have higher incidence rates than their ovarian homologues.
  • In contrast, after age 50 (menopause), the incidence rates begin to diverge: the rates for uterine endometrial carcinomas continue to rise, whereas the rates for ovarian endometrioid carcinomas plateau.
  • Interestingly, endometrial stromal sarcomas follow an incidence rate pattern nearly identical to that of ovarian endometrioid carcinomas.
  • CONCLUSIONS: The continuum of cellular and molecular events predisposing to gynecologic cancers of endometrioid phenotype apparently cease to operate in the ovary after menopause, but additional cellular and molecular events appear to occur in the ageing uterine endometrium.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology. Ovarian Neoplasms / pathology. SEER Program. Uterine Neoplasms / pathology
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Endometrium / pathology. Female. Humans. Incidence. Middle Aged. United States / epidemiology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17824787.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Farias-Eisner G, Su F, Robbins T, Kotlerman J, Reddy S, Farias-Eisner R: Validation of serum biomarkers for detection of early- and late-stage endometrial cancer. Am J Obstet Gynecol; 2010 Jan;202(1):73.e1-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Validation of serum biomarkers for detection of early- and late-stage endometrial cancer.
  • OBJECTIVE: The objective of this study was to determine the efficacy of 3 previously described ovarian cancer serum biomarkers (apolipoprotein-1 [ApoA-I], prealbumin [TTR], transferrin [TF]) in the detection of endometrioid and papillary serous adenocarcinoma of the endometrium.
  • STUDY DESIGN: ApoA-I, TTR, and TF levels were measured in serum samples that were obtained from 433 individuals that included 90 women with normal endometrium, 210 women with early-stage endometrial cancer, and 133 women with late-stage endometrial cancer.
  • Multivariate regression models were constructed to evaluate the usefulness of the biomarkers in the detection of endometrial cancer.
  • RESULTS: ApoA-I, TTR, and TF distinguished normal samples from early-stage endometrial cancer with a sensitivity of 71% (specificity, 88%) and normal samples from late stage endometrial cancer with a sensitivity of 82% (specificity, 86%).
  • CONCLUSION: The biomarker panel that consists of ApoA-I, TTR, and TF may prove to be a useful clinical tool for the detection of endometrial cancer.
  • [MeSH-major] Adenocarcinoma / diagnosis. Apolipoprotein A-I / blood. Biomarkers, Tumor / blood. CA-125 Antigen / blood. Endometrial Neoplasms / diagnosis. Prealbumin / analysis. Transferrin / analysis
  • [MeSH-minor] Adenocarcinoma, Clear Cell / diagnosis. Adult. Female. Humans. Neoplasm Staging. Regression Analysis. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Endometrial cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Mosby, Inc.
  • (PMID = 19766980.001).
  • [ISSN] 1097-6868
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apolipoprotein A-I; 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / Prealbumin; 0 / Transferrin
  •  go-up   go-down


48. Phupong V, Khemapech N, Triratanachat S: Triple synchronous primary cervical, endometrial and ovarian cancer with four different histologic patterns. Arch Gynecol Obstet; 2007 Dec;276(6):655-8
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Triple synchronous primary cervical, endometrial and ovarian cancer with four different histologic patterns.
  • The preoperative evaluation and diagnosis was myoma uteri with bilateral ovarian tumor.
  • The postoperative and pathologic findings were adenosquamous carcinoma of the endocervix, adenocarcinoma of the endometrium, low malignant potential of the right ovary and mucinous cystadenocarcinoma of the left ovary.
  • [MeSH-major] Endometrial Neoplasms / pathology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adenofibroma / pathology. Carcinoma, Adenosquamous / pathology. Cystadenoma, Mucinous / pathology. Female. Humans. Middle Aged


49. Horrée N, van Diest PJ, van der Groep P, Sie-Go DM, Heintz AP: Hypoxia and angiogenesis in endometrioid endometrial carcinogenesis. Cell Oncol; 2007;29(3):219-27

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypoxia and angiogenesis in endometrioid endometrial carcinogenesis.
  • METHODS: Expression of HIF-1alpha and proteins in the HIF-1alpha pathway (Glut-1, CAIX, VEGF) in paraffin-embedded specimens of normal (n=17), premalignant (n=17) and endometrioid endometrial carcinoma (n=39) was explored by immunohistochemistry, in relation to microvessel density (MVD).
  • RESULTS: HIF-1alpha overexpression was absent in inactive endometrium but present in hyperplasia (61%) and carcinoma (87%), with increasing expression in a perinecrotic fashion pointing to underlying hypoxia.
  • No membranous expression of Glut-1 and CAIX was noticed in inactive endometrium, in contrast with expression in hyperplasia (Glut-1 0%, CAIX 61%, only focal and diffuse) and carcinoma (Glut-1 94.6%, CAIX 92%, both mostly perinecrotically).
  • VEGF was significantly higher expressed in hyperplasias and carcinomas compared to inactive endometrium.
  • MVD was higher in hyperplasias and carcinomas than in normal endometrium (p<0.001).
  • CONCLUSION: HIF-1alpha and its downstream genes are increasingly expressed from normal through premalignant to endometrioid adenocarcinoma of the endometrium, paralleled by activation of its downstream genes and increased angiogenesis.
  • This underlines the potential importance of hypoxia and its key regulator HIF-1alpha in endometrial carcinogenesis.
  • [MeSH-major] Carcinoma, Endometrioid / blood supply. Carcinoma, Endometrioid / metabolism. Neovascularization, Pathologic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17452774.001).
  • [ISSN] 1570-5870
  • [Journal-full-title] Cellular oncology : the official journal of the International Society for Cellular Oncology
  • [ISO-abbreviation] Cell. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibodies; 0 / Glucose Transporter Type 1; 0 / Hypoxia-Inducible Factor 1, alpha Subunit
  • [Other-IDs] NLM/ PMC4618415
  •  go-up   go-down


50. McKenney JK, Longacre TA: Low-grade endometrial adenocarcinoma: a diagnostic algorithm for distinguishing atypical endometrial hyperplasia and other benign (and malignant) mimics. Adv Anat Pathol; 2009 Jan;16(1):1-22
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-grade endometrial adenocarcinoma: a diagnostic algorithm for distinguishing atypical endometrial hyperplasia and other benign (and malignant) mimics.
  • The distinction between endometrial hyperplasia and well-differentiated adenocarcinoma of the endometrium continues to be a difficult differential diagnosis in surgical pathology.
  • Evidence-based diagnostic criteria for well-differentiated endometrial adenocarcinoma focus on histologic features that predict myoinvasion in the hysterectomy specimen.
  • Application of these 2 criteria in problematic endometrial proliferations allows stratification of patients into 3 risk categories: very low risk (< 0.05% risk of myoinvasion at hysterectomy)=complex atypical hyperplasia; intermediate risk (5.5% risk of myoinvasion at hysterectomy)=complex atypical hyperplasia, cannot exclude well-differentiated adenocarcinoma (borderline); and high risk (20% risk of myoinvasion at hysterectomy)=well-differentiated adenocarcinoma.
  • In order to optimize the use of these diagnostic criteria, a variety of gland forming lesions that may mimic well-differentiated endometrioid adenocarcinoma must first be excluded.
  • In addition, unusual morphologic patterns of low-grade endometrioid adenocarcinoma should be recognized, as they may cause confusion with other, higher grade (and therefore, more clinically aggressive) endometrial processes.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology. Endometrium / pathology. Uterine Diseases / pathology
  • [MeSH-minor] Algorithms. Cell Division. Diagnosis, Differential. Female. Humans. Hyperplasia. Kinetics. Metaplasia / pathology. Neoplasm Invasiveness. Risk Assessment

  • MedlinePlus Health Information. consumer health - Uterine Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19098463.001).
  • [ISSN] 1533-4031
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 58
  •  go-up   go-down


51. Moxley KM, McMeekin DS: Endometrial carcinoma: a review of chemotherapy, drug resistance, and the search for new agents. Oncologist; 2010;15(10):1026-33
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial carcinoma: a review of chemotherapy, drug resistance, and the search for new agents.
  • Adenocarcinoma of the endometrium represents the most common gynecologic malignancy in developed countries.
  • Chemotherapy has evolved into an important modality in high-risk early-stage and advanced-stage disease, and in recurrent endometrial cancer.
  • Taxane-based therapy consistently demonstrates the highest response rates in the first-line and salvage settings of endometrial cancer.
  • Epothilone B analogs are novel cytotoxic agents with activity in solid tumors, including advanced/recurrent endometrial carcinoma, and may have unique properties that can overcome resistance in some settings.
  • These agents alone and in combination represent a new therapeutic opportunity in endometrial carcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Endometrial Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 2003 Mar;14(3):441-8 [12598351.001]
  • [Cites] J Surg Res. 2001 Aug;99(2):179-86 [11469885.001]
  • [Cites] Gynecol Oncol. 2004 Mar;92(3):744-51 [14984936.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2159-66 [15169803.001]
  • [Cites] Ann Oncol. 2004 Aug;15(8):1173-8 [15277255.001]
  • [Cites] J Clin Oncol. 2004 Oct 1;22(19):3902-8 [15459211.001]
  • [Cites] Am J Obstet Gynecol. 1992 Nov;167(5):1317-25 [1442985.001]
  • [Cites] Eur J Cancer. 1993;29A(4):554-8 [8094623.001]
  • [Cites] Cell Struct Funct. 1993 Jun;18(3):173-82 [7902216.001]
  • [Cites] Cancer Res. 1995 Jun 1;55(11):2325-33 [7757983.001]
  • [Cites] Int J Cancer. 1995 Dec 11;63(6):798-803 [8847137.001]
  • [Cites] Gynecol Oncol. 1996 Aug;62(2):278-81 [8751561.001]
  • [Cites] J Biol Chem. 1997 Jan 24;272(4):2534-41 [8999970.001]
  • [Cites] J Biol Chem. 1997 Jul 4;272(27):17118-25 [9202030.001]
  • [Cites] J Clin Invest. 1997 Sep 1;100(5):1282-93 [9276747.001]
  • [Cites] J Natl Cancer Inst. 1998 Sep 16;90(18):1371-88 [9747868.001]
  • [Cites] Oncol Rep. 1999 Nov-Dec;6(6):1377-82 [10523715.001]
  • [Cites] J Natl Cancer Inst. 2004 Nov 3;96(21):1635-8 [15523093.001]
  • [Cites] J Clin Oncol. 2006 Jan 1;24(1):36-44 [16330675.001]
  • [Cites] Clin Cancer Res. 2006 May 1;12(9):2774-9 [16675570.001]
  • [Cites] Br J Cancer. 2006 Aug 7;95(3):266-71 [16868539.001]
  • [Cites] Gynecol Oncol. 2006 Oct;103(1):155-9 [16545437.001]
  • [Cites] Int J Gynaecol Obstet. 2006 Nov;95 Suppl 1:S105-43 [17161155.001]
  • [Cites] Gynecol Oncol. 2007 Jul;106(1):16-22 [17574073.001]
  • [Cites] J Clin Oncol. 2007 Jul 10;25(20):2983-90 [17617530.001]
  • [Cites] Gynecol Oncol. 2008 Jan;108(1):226-33 [17996926.001]
  • [Cites] Apoptosis. 2008 Feb;13(2):259-71 [18071906.001]
  • [Cites] Obstet Gynecol. 2008 Feb;111(2 Pt 1):436-47 [18238985.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Int J Gynecol Pathol. 2008 Apr;27(2):207-12 [18317222.001]
  • [Cites] Ann Oncol. 2008 May;19 Suppl 2:ii19-20 [18456753.001]
  • [Cites] Cancer Chemother Pharmacol. 2008 Dec;63(1):157-66 [18347795.001]
  • [Cites] Clin Ther. 2008 Sep;30(9):1590-617 [18840366.001]
  • [Cites] Gynecol Oncol. 2008 Oct;111(1):22-6 [18675446.001]
  • [Cites] Cancer Res. 2008 Dec 15;68(24):10197-204 [19074887.001]
  • [Cites] Clin Cancer Res. 2008 Dec 15;14(24):8123-31 [19088027.001]
  • [Cites] Oncologist. 2008 Dec;13(12):1207-23 [19088324.001]
  • [Cites] Mol Cancer Ther. 2009 Jan;8(1):17-25 [19139109.001]
  • [Cites] Gynecol Oncol. 2009 Mar;112(3):543-52 [19108877.001]
  • [Cites] Int J Gynaecol Obstet. 2009 May;105(2):103-4 [19367689.001]
  • [Cites] J Biol Chem. 2009 May 8;284(19):13023-32 [19282281.001]
  • [Cites] Endocr Relat Cancer. 2009 Jun;16(2):363-80 [19190080.001]
  • [Cites] J Clin Oncol. 2009 Jul 1;27(19):3104-8 [19451430.001]
  • [Cites] J Clin Oncol. 2009 Nov 10;27(32):5331-6 [19805679.001]
  • [Cites] Eur J Gynaecol Oncol. 2009;30(5):514-7 [19899405.001]
  • [Cites] J Clin Oncol. 2010 Jan 1;28(1):149-53 [19917861.001]
  • [Cites] Mol Cancer Ther. 2009 May;8(5):1055-66 [19435871.001]
  • [Cites] J Clin Oncol. 1999 Jun;17(6):1786-93 [10561216.001]
  • [Cites] Lancet. 2000 Apr 22;355(9213):1404-11 [10791524.001]
  • [Cites] Biochim Biophys Acta. 2001;1471(2):O1-9 [11342188.001]
  • [Cites] Gynecol Oncol. 2003 Mar;88(3):277-81 [12648575.001]
  • (PMID = 20930101.001).
  • [ISSN] 1549-490X
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ PMC3227900
  •  go-up   go-down


52. Powell JL, Cunill ES, Gajewski WH, Novotny DB: Sarcoidosis mimicking recurrent endometrial cancer. Gynecol Oncol; 2005 Dec;99(3):770-3
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sarcoidosis mimicking recurrent endometrial cancer.
  • BACKGROUND: Sarcoidosis is a multisystem disease and can be confused with benign or malignant tumors.
  • In patients with recurrent gynecologic cancer, liver and intrathoracic lesions should undergo a biopsy to rule in metastatic malignancy, as clinical findings and CAT scan results may represent other disease processes.
  • CASE: A 67 year old woman had a total abdominal hysterectomy, bilateral salpingo-oophorectomy, pelvic and periaortic lymphadenectomy, and peritoneal cytology in 2001 for Stage I B grade 1 adenocarcinoma of the endometrium.
  • [MeSH-major] Endometrial Neoplasms / diagnosis. Neoplasm Recurrence, Local / diagnosis. Sarcoidosis / diagnosis
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Neoplasm Metastasis

  • Genetic Alliance. consumer health - Sarcoidosis.
  • Genetic Alliance. consumer health - Endometrial cancer.
  • MedlinePlus Health Information. consumer health - Sarcoidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16168469.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Akbulut M, Tosun H, Soysal ME, Oztekin O: Endometrioid carcinoma of the endometrium with choriocarcinomatous differentiation: a case report and review of the literature. Arch Gynecol Obstet; 2008 Jul;278(1):79-84

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrioid carcinoma of the endometrium with choriocarcinomatous differentiation: a case report and review of the literature.
  • OBJECTIVE: An endometrioid adenocarcinoma (EAC) with true trophoblastic differentiation is a rare event with a highly aggressive clinical course.
  • CASE: We report an endometrioid adenocarcinoma of the endometrium in which there was a morphologically conventional-appearing EAC component admixed with multinucleated giant cells and large pleomorphic tumor cells that resembled a choriocarcinoma without an elevated serum level of human chorionic gonadotropin (hCG) in a 42-year-old unmarried woman with a history of abnormal uterine bleeding.
  • Histopathologic study of the specimen showed endometrioid adenocarcinoma extended to the deep myometrium with a focus of hemorrhagic and necrotic tumor composed of multinucleated giant cells, large pleomorphic tumor cells, suggesting choriocarcinomatous differentiation (CD).
  • Immunohistochemical studies demonstrated intense reactivity of tumor cells for human chorionic gonadotropin (hCG) confirming the diagnosis.
  • CONCLUSION: Although endometrioid adenocarcinoma with choriocarcinomatous differentiation is known to behave in a more aggressive course, this disease may have a good prognosis with a clinically indolent course when it is small, and without elevated serum hCG levels.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Choriocarcinoma / pathology. Endometrial Neoplasms / pathology. Neoplasms, Multiple Primary / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18066564.001).
  • [ISSN] 0932-0067
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin
  • [Number-of-references] 24
  •  go-up   go-down


54. Tamura T, Jobo T, Watanabe J, Kanai T, Kuramoto H: Neuroendocrine features in poorly differentiated endometrioid adenocarcinomas of the endometrium. Int J Gynecol Cancer; 2006 Mar-Apr;16(2):821-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuroendocrine features in poorly differentiated endometrioid adenocarcinomas of the endometrium.
  • This study aimed to clarify neuroendocrine features (NEF) in poorly differentiated (G3) endometrioid adenocarcinoma of the endometrium and to evaluate its prognostic significance.
  • Forty cases with G3 carcinoma were investigated for NEF immunohistochemically.
  • A patient with diffusely positive staining for both chromogranin A and synaptophysin was diagnosed with neuroendocrine carcinoma.
  • NEF was detected immunohistochemically in approximately 63% of the G3 carcinomas, and these patients had a poor prognosis.
  • [MeSH-major] Adenocarcinoma / pathology. Biomarkers, Tumor / metabolism. Endometrial Neoplasms / pathology. Neurosecretory Systems / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16681768.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD57; 0 / Biomarkers, Tumor; 0 / Chromogranin A; 0 / Chromogranins; 0 / Synaptophysin
  •  go-up   go-down


55. Kondalsamy-Chennakesavan S, van Vugt S, Sanday K, Nicklin J, Land R, Perrin L, Crandon A, Obermair A: Evaluation of tumor-free distance and depth of myometrial invasion as prognostic factors for lymph node metastases in endometrial cancer. Int J Gynecol Cancer; 2010 Oct;20(7):1217-21
Genetic Alliance. consumer health - Endometrial cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of tumor-free distance and depth of myometrial invasion as prognostic factors for lymph node metastases in endometrial cancer.
  • INTRODUCTION: Concurrent uterine lesions or an irregular endomyometrial junction can make accurate assessment of depth of myometrial invasion (DOI) and percentage of myometrial invasion (%MI) difficult, leading to patients being staged and or treated suboptimally.
  • An alternative measurement, known as the tumor-free distance (TFD), which measures the distance between maximal myometrial invasion and the uterine serosa, has been proposed.
  • Our objective was to compare TFD, DOI, and %MI as predictors for lymph node involvement in surgically staged endometrial cancer patients.
  • METHODS: Patients with endometrioid adenocarcinoma of the endometrium treated between January 1997 and December 2007 were included.
  • [MeSH-major] Carcinoma, Endometrioid / secondary. Endometrial Neoplasms / pathology. Lymph Nodes / pathology. Myometrium / pathology. Neoplasm Recurrence, Local / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21495232.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Li HW, Leung SW, Chan CS, Yu MM, Wong YF: Expression of maspin in endometrioid adenocarcinoma of endometrium. Oncol Rep; 2007 Feb;17(2):393-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of maspin in endometrioid adenocarcinoma of endometrium.
  • Underexpression of maspin has been reported in breast and prostatic cancers, but in some cancers such as ovarian, colorectal and pancreatic carcinoma, it was found to be up-regulated.
  • This study aimed at demonstrating the expression of maspin in human endometrial tissue and searching for any altered expression in endometrioid adenocarcinoma of the endometrium compared to normal endometrium.
  • The expression level of the maspin gene was studied using reverse transcriptase-polymerase chain reaction (RT-PCR) performed on RNA extracted from 34 endometrial cancer samples (including 24 with FIGO stage I disease and 10 with FIGO stage III disease) and 28 normal endometrium in proliferative or secretory phases.
  • Immunohistochemical staining was also performed on 10 cases of endometrial cancer (6 FIGO stage I cases and 4 FIGO stage III cases) as well as 15 normal endometrium.
  • Semi-quantitative RT-PCR revealed that the expression of maspin was significantly up-regulated in both stage I (p<0.01) and stage III (p<0.01) endometrial cancer compared with normal endometrium.
  • However, no significant difference in maspin expression was demonstrated between stage I and stage III endometrial cancer.
  • Immunostaining of all tissue sections revealed an immunopositive signal in the nuclei of the normal or cancerous endometrial glandular cells.
  • In 60% of the cancer cases, cytoplasmic staining was also evident.
  • Our results suggested that there is up-regulated expression of maspin in endometrioid endometrial adenocarcinoma.
  • Cytoplasmic immuno-expression of maspin is common in endometrial cancer.
  • It may play a role in the malignant transformation of human endometrial tissue.
  • [MeSH-major] Carcinoma, Endometrioid / metabolism. Endometrial Neoplasms / metabolism. Endometrium / metabolism. Gene Expression Regulation, Neoplastic. Serpins / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17203179.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / DNA Primers; 0 / SERPIN-B5; 0 / Serpins
  •  go-up   go-down


57. Takacs P, De Santis T, Nicholas MC, Verma U, Strassberg R, Duthely L: Echogenic endometrial fluid collection in postmenopausal women is a significant risk factor for disease. J Ultrasound Med; 2005 Nov;24(11):1477-81
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Echogenic endometrial fluid collection in postmenopausal women is a significant risk factor for disease.
  • OBJECTIVE: The purpose of this study was to assess postmenopausal women with endometrial fluid collection and the risk of significant endometrial or cervical disease.
  • METHODS: A retrospective chart review was conducted of 343 postmenopausal women with endometrial fluid collection on pelvic sonography.
  • Medical records were reviewed to identify women who underwent an evaluation of the endometrium with endometrial biopsy, hysteroscopy, or hysterectomy after the sonographic examination.
  • Clinical and sonographic characteristics were compared between women with diagnoses of cervical or endometrial cancer or hyperplasia (nonbenign group) and women with benign conditions (benign group).
  • RESULTS: The endometrium was significantly thicker in the nonbenign group compared with the benign group (mean +/- SD, 9.9 +/- 7.4 versus 5.9 +/- 4.1 mm; P = .016).
  • None of the patients with adenocarcinoma of the endometrium had endometrial thickness of 3 mm or less, but 2 with endocervical cancer did.
  • Echogenic fluid in the endometrial cavity was significantly more likely to be found in the nonbenign group compared with the benign group (45.8% versus 4.8%; P < .01).
  • Multivariate logistic regression analysis revealed that echogenic fluid in the endometrial cavity was the only significant risk factor for nonbenign conditions (odds ratio, 10.94; 95% confidence interval, 2.67-44.84; P < .01).
  • CONCLUSIONS: Postmenopausal women with endometrial fluid collection on sonography should undergo endometrial sampling if the endometrial lining is thicker than 3 mm or the endometrial fluid is echogenic.
  • If the lining is 3 mm or less and the endometrial fluid is clear, endometrial sampling is not necessary, but we recommend endocervical sampling to rule out endocervical cancer.
  • [MeSH-major] Endometrium. Postmenopause. Uterine Cervical Diseases / ultrasonography
  • [MeSH-minor] Body Fluids. Female. Humans. Middle Aged. Retrospective Studies. Risk Factors. Uterine Diseases / ultrasonography

  • MedlinePlus Health Information. consumer health - Cervix Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16239648.001).
  • [ISSN] 0278-4297
  • [Journal-full-title] Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
  • [ISO-abbreviation] J Ultrasound Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Trimble CL, Kauderer J, Zaino R, Silverberg S, Lim PC, Burke JJ 2nd, Alberts D, Curtin J: Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Cancer; 2006 Feb 15;106(4):812-9
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study.
  • BACKGROUND: Adenocarcinoma of the endometrium is the most common gynecologic malignancy in the United States, accounting for approximately 36,000 diagnoses of invasive carcinoma annually.
  • The most common histologic type, endometrioid adenocarcinoma (EC), accounts for 75-80% of patients.
  • The objective of this work was to estimate the prevalence of concurrent carcinoma in women with a biopsy diagnosis of the precursor lesion, atypical endometrial hyperplasia (AEH).
  • METHODS: This prospective cohort study included women who had a community diagnosis of AEH.
  • Of these, 17 women were not included in the analysis: Two patients had unreadable slides because of poor processing or insufficient tissue, 2 patients had only slides that were not endometrial, the slides for 5 patients were not available for review, and 8 of the hysterectomy specimens were excluded because they showed evidence of interval intervention, either progestin effect or ablation.
  • The study panel review of the AEH biopsy specimens was interpreted as follows: 74 of 289 specimens (25.6%) were diagnosed as less than AEH, 115 of 289 specimens (39.8%) were diagnosed as AEH, and 84 of 289 specimens (29.1%) were diagnosed as endometrial carcinoma.
  • In 5.5% (16 of 289 specimens), there was no consensus on the biopsy diagnosis.
  • The rate of concurrent endometrial carcinoma for analyzed specimens was 42.6% (123 of 289 specimens).
  • Among the women who had hysterectomy specimens with carcinoma, 14 of 74 women (18.9%) had a study panel biopsy consensus diagnosis of less than AEH, 45 of 115 women (39.1%) had a study panel biopsy consensus diagnosis of AEH, and 54 of 84 women (64.3%) had a study panel diagnosis of carcinoma.
  • Among women who had no consensus in their biopsy diagnosis, 10 of 16 women (62.5%) had carcinoma in their hysterectomy specimens.
  • CONCLUSIONS: The prevalence of endometrial carcinoma in patients who had a community hospital biopsy diagnosis of AEH was high (42.6%).
  • When considering management strategies for women who have a biopsy diagnosis of AEH, clinicians and patients should take into account the considerable rate of concurrent carcinoma.
  • [MeSH-major] Adenocarcinoma / epidemiology. Endometrial Hyperplasia / complications. Endometrial Hyperplasia / pathology. Endometrial Neoplasms / epidemiology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 American Cancer Society.
  • [CommentIn] Cancer. 2006 Feb 15;106(4):729-31 [16400641.001]
  • (PMID = 16400639.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 27469; United States / NCI NIH HHS / CA / CA 37517
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


59. Niazi TM, Souhami L, Portelance L, Bahoric B, Gilbert L, Stanimir G: Long-term results of high-dose-rate brachytherapy in the primary treatment of medically inoperable stage I-II endometrial carcinoma. Int J Radiat Oncol Biol Phys; 2005 Nov 15;63(4):1108-13

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results of high-dose-rate brachytherapy in the primary treatment of medically inoperable stage I-II endometrial carcinoma.
  • PURPOSE: Total-abdominal hysterectomy and bilateral salpingo-oophorectomy (TAHBSO) is the gold-standard therapy for patients with endometrial carcinoma.
  • METHODS AND MATERIALS: Between 1984 and 2003, 38 patients with Stage I and Stage II adenocarcinoma of the endometrium considered high operative risk received RT as the primary treatment.
  • CONCLUSION: Medically inoperable Stage I endometrial carcinoma may be safely and effectively treated with HDRB as the primary therapy.
  • We believe that the alternative option of HDRB as the primary therapy for selected Stage I endometrial carcinoma, even in patients with low operative risks, needs further evaluation.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Brachytherapy / methods. Endometrial Neoplasms / radiotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16099598.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Legro RS, Zaino RJ, Demers LM, Kunselman AR, Gnatuk CL, Williams NI, Dodson WC: The effects of metformin and rosiglitazone, alone and in combination, on the ovary and endometrium in polycystic ovary syndrome. Am J Obstet Gynecol; 2007 Apr;196(4):402.e1-10; discussion 402.e10-1
Hazardous Substances Data Bank. ROSIGLITAZONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effects of metformin and rosiglitazone, alone and in combination, on the ovary and endometrium in polycystic ovary syndrome.
  • OBJECTIVE: To examine the effects of metformin and rosiglitazone, alone and in combination, on endometrial histology and ovarian steroid production.
  • RESULTS: Abnormal endometrial histology was found in 3 subjects at baseline, including 1 case of adenocarcinoma of the endometrium in an asymptomatic subject, who was excluded from further study.
  • CONCLUSION: This study provides preliminary evidence that insulin-sensitizing drugs may have beneficial effects on the endometrium, although the exact mechanism beyond improving ovulatory function is still unknown.
  • [MeSH-major] Endometrium / pathology. Metformin / therapeutic use. Ovary / pathology. Polycystic Ovary Syndrome / drug therapy. Thiazolidinediones / therapeutic use

  • MedlinePlus Health Information. consumer health - Polycystic Ovary Syndrome.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. METFORMIN HYDROCHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17403436.001).
  • [ISSN] 1097-6868
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / C06 RR016499; United States / NICHD NIH HHS / HD / K24 HD001476; United States / NCRR NIH HHS / RR / M01 RR010732
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Thiazolidinediones; 05V02F2KDG / rosiglitazone; 9100L32L2N / Metformin
  •  go-up   go-down


61. Jolly S, Vargas C, Kumar T, Weiner S, Brabbins D, Chen P, Floyd W, Martinez AA: Vaginal brachytherapy alone: an alternative to adjuvant whole pelvis radiation for early stage endometrial cancer. Gynecol Oncol; 2005 Jun;97(3):887-92
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vaginal brachytherapy alone: an alternative to adjuvant whole pelvis radiation for early stage endometrial cancer.
  • OBJECTIVE: Postoperative management of early stage adenocarcinoma of the endometrium remains controversial.
  • The use of pelvic radiation therapy as shown by the Gynecologic Oncology Group (GOG)-99 trial improves the event free interval at the cost of increased toxicity.
  • We reviewed and compared our results treating early stage endometrial adenocarcinoma using hypofractionated high dose rate (HDR) vaginal brachytherapy (VB) alone with the results of the GOG-99.
  • METHODS: From 1992 to 2002, 243 endometrial cancer patients were treated with TAH/BSO and selective lymph node dissection followed by adjuvant radiotherapy (RT).
  • Of these, 50 FIGO stage I-II (occult) adenocarcinoma (no clear cell or serous papillary) of the endometrium were managed with HDR hypofractionated VB as monotherapy using Iridium-192 to a dose of 30 Gy in 6 fractions twice weekly prescribed to a depth of 5 mm and median length of 4 cm.
  • In our study, one patient failed in the vagina alone and a second patient failed in the vagina and pelvis.
  • CONCLUSION: Stage I-II (occult) endometrial adenocarcinoma treated with postoperative HDR vaginal brachytherapy has similar overall survival, locoregional failure rates, and cumulative recurrence rates to standard fractionation external beam pelvic RT with the benefit of much lower toxicity rates and shorter overall treatment time.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Brachytherapy / methods. Endometrial Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Vaginal cancer.
  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15943991.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


62. Bermudez Wagner KM, Thomas MB, Miyamoto C, Micaily B, Hernandez E: Tailored surgical staging and radiation therapy in clinical stage I endometrioid endometrial adenocarcinoma (EEA). J Clin Oncol; 2009 May 20;27(15_suppl):e16511

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tailored surgical staging and radiation therapy in clinical stage I endometrioid endometrial adenocarcinoma (EEA).
  • : e16511 Background: Pelvic lymph node dissection (LND) requirement to adequately stage endometrial cancer has been subject of debate.
  • We conducted an outcome analysis of clinical stage I endometrioid endometrial adenocarcinoma (EEA) patients who underwent surgery with tailored LND and adjuvant therapy (radiation (RT) or chemotherapy) between 1997 and 2008.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960757.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Fadare O, Desrosiers L, Xiao ZF, Wang SA: How often does cervical involvement upstage patients with non-myoinvasive (otherwise stage 1A) endometrioid adenocarcinoma of the endometrium? Virchows Arch; 2007 May;450(5):601-2
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] How often does cervical involvement upstage patients with non-myoinvasive (otherwise stage 1A) endometrioid adenocarcinoma of the endometrium?
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / pathology. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Combined Modality Therapy. Diagnosis, Differential. Female. Humans. Neoplasm Invasiveness. Prognosis


64. Kurotaki T, Kokoshima H, Kitamori F, Kitamori T, Tsuchitani M: A case of adenocarcinoma of the endometrium extending into the leiomyoma of the uterus in a rabbit. J Vet Med Sci; 2007 Sep;69(9):981-4
MedlinePlus Health Information. consumer health - Uterine Fibroids.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of adenocarcinoma of the endometrium extending into the leiomyoma of the uterus in a rabbit.
  • In a pet rabbit, 2 tumor masses one on each horn were macroscopically seen in the wall of the uterus.
  • The tumor was diagnosed as an adenocarcinoma of the endometrium.
  • While adenocarcinoma cells formed a protrusive mass in the uterine lumen, they also showed an extension into the leiomyoma of the myometrium.
  • By immunohistochemistry, adenocarcinoma stained positive for cytokeratin (MNF116) and leiomyoma stained positive for smooth muscle actin, showing a substantial difference in the cytological nature of these tumor cells.
  • The results may give a further evidence supporting the narrative of the tumor development that an adenocarcinoma of the endometrium extended into leiomyoma of the uterus.

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17917388.001).
  • [ISSN] 0916-7250
  • [Journal-full-title] The Journal of veterinary medical science
  • [ISO-abbreviation] J. Vet. Med. Sci.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


65. Bigsby GE 4th, Holloway RW, Weppelman B, Reynolds RB, Williams B: Endometroid adenocarcinoma of the uterus with cardiac metastasis. A case report and six-year follow-up. Gynecol Oncol; 2005 Apr;97(1):256-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometroid adenocarcinoma of the uterus with cardiac metastasis. A case report and six-year follow-up.
  • BACKGROUND: There are few reported cases of cardiac metastasis associated with endometrial cancer (EC) and no reports of long-term survival.
  • A total abdominal hysterectomy with pelvic and para-aortic lymhadenectomy was performed with disease confined to the uterus/cervix.
  • [MeSH-major] Adenocarcinoma / secondary. Endometrial Neoplasms / pathology. Heart Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15790471.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Oztürk HB, Vural B, Calışkan E, Solakoğlu S: Effect of GnRH analogues and octreotide treatment on apoptosis and the cell proliferation of endometrium adenocarcinoma cell lines. J Turk Ger Gynecol Assoc; 2010;11(3):131-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of GnRH analogues and octreotide treatment on apoptosis and the cell proliferation of endometrium adenocarcinoma cell lines.
  • OBJECTIVE: The aim of this study was to compare apoptotic and antiproliferative effects of gonadotropin-releasing hormone analogues and their combination with octeotide on endometrioid endometrial cancer cell lines.
  • MATERIAL AND METHOD: Women diagnosed with endometrioid adenocarcinoma at the department of Gynecology and Obstetric of Kocaeli University Medical School were included in this research.
  • Endometrium cancer cell lines obtained from three patients were used for this study.
  • CONCLUSION: GnRH analogues appears to have a direct effect, enhancing the apoptotic index and decreasing the cell proliferation in endometrial adenocancer cell lines.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24591918.001).
  • [ISSN] 1309-0399
  • [Journal-full-title] Journal of the Turkish German Gynecological Association
  • [ISO-abbreviation] J Turk Ger Gynecol Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Turkey
  • [Other-IDs] NLM/ PMC3939219
  • [Keywords] NOTNLM ; Endometrial cancer / apoptosis / cell proliferation / gonadotropin-releasing hormone analogues / octreotide
  •  go-up   go-down


67. Ackerman I: Adjuvant pelvic radiation therapy in endometrial cancer: The pro argument. Int J Gynecol Cancer; 2010 Oct;20(11 Suppl 2):S67-9
Genetic Alliance. consumer health - Endometrial cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant pelvic radiation therapy in endometrial cancer: The pro argument.
  • Adjuvant external beam pelvic radiation therapy for stage I endometrial cancer has become increasingly confusing and controversial.
  • By using evidence from the literature, including the most recent randomized data, an argument is made for the use of external beam pelvic radiotherapy for a 63-year-old woman who has undergone a total abdominal hysterectomy and bilateral salpingo-oophorectomy for a grade 2 endometrioid adenocarcinoma of the uterus with 9 of 12 mm of invasion and the presence of lymphovascular space involvement.
  • [MeSH-major] Carcinoma, Endometrioid / prevention & control. Carcinoma, Endometrioid / radiotherapy. Endometrial Neoplasms / prevention & control. Endometrial Neoplasms / radiotherapy. Neoplasm Recurrence, Local / prevention & control

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21053530.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


68. Cutillo G, Cignini P, Visca P, Vizza E, Sbiroli C: Endometrial biopsy by means of the hysteroscopic resectoscope for the evaluation of tumor differentiation in endometrial cancer: a pilot study. Eur J Surg Oncol; 2007 Sep;33(7):907-10
Genetic Alliance. consumer health - Endometrial cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial biopsy by means of the hysteroscopic resectoscope for the evaluation of tumor differentiation in endometrial cancer: a pilot study.
  • AIMS: To assess the diagnostic accuracy of endometrial biopsy by means of the hysteroscopic resectoscope (EBHR) in evaluating tumor differentiation in patients with endometrial cancer.
  • METHODS: Between January and December 2005, all the women with a diagnosis of endometrioid adenocarcinoma of the uterus, when admitted to hospital, were enrolled for this study.
  • CONCLUSION: EBHR is a very accurate diagnostic procedure for assessing the preoperative tumor grade in patients with endometrial cancer.
  • [MeSH-major] Endometrial Neoplasms / pathology. Endometrium / pathology. Hysteroscopes. Hysteroscopy / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur J Surg Oncol. 2007 Oct;33(8):1047-8 [17336480.001]
  • (PMID = 17188830.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


69. Moore RG, Brown AK, Miller MC, Badgwell D, Lu Z, Allard WJ, Granai CO, Bast RC Jr, Lu K: Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. Gynecol Oncol; 2008 Aug;110(2):196-201
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus.
  • OBJECTIVE: Tumor markers with increased sensitivity and specificity for endometrial cancer are needed to help monitor response to therapy and to detect recurrent disease.
  • The objectives of this study were to examine the levels of several novel tumor markers HE4, SMRP, CA72.4 and CA125 as potential markers in patients diagnosed with endometrioid adenocarcinoma of the uterus.
  • METHODS: Pre-operative serum samples from surgically staged patients with endometrioid adenocarcinoma of the uterus were analyzed for levels of HE4, SMRP, CA72-4 and CA125.
  • RESULTS: Serum samples from 156 healthy subjects and 171 patients with endometrial cancer (122 stage I, 17 stage II, 26 stage III, and 6 stage IV) were analyzed.
  • At a 95% specificity, the sensitivities for differentiating between healthy subjects and all stages of cancer were 45.5% for HE4 and 24.6% for CA125.
  • CONCLUSION: HE4 is elevated in all stages of endometrial can100cer and is more sensitive in early-stage endometrial cancer compared to CA125.
  • Further investigation of HE4 as a marker for early detection of recurrent endometrial cancer and monitoring response to therapy is warranted.
  • [MeSH-major] Adenocarcinoma / blood. Biomarkers, Tumor / blood. Endometrial Neoplasms / blood. Epididymal Secretory Proteins / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, Tumor-Associated, Carbohydrate / blood. CA-125 Antigen / blood. Female. GPI-Linked Proteins. Humans. Membrane Glycoproteins / blood. Middle Aged. Neoplasm Staging. Sensitivity and Specificity. beta-Defensins

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2002 Jul;86(1):28-33 [12079296.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Gynecol Oncol. 2003 May;89(2):201-9 [12713981.001]
  • [Cites] Am J Obstet Gynecol. 2003 May;188(5):1195-7 [12748476.001]
  • [Cites] Gynecol Oncol. 2004 Mar;92(3):744-51 [14984936.001]
  • [Cites] J Proteome Res. 2004 May-Jun;3(3):636-43 [15253447.001]
  • [Cites] Am J Obstet Gynecol. 1984 Apr 15;148(8):1057-8 [6201072.001]
  • [Cites] Am J Obstet Gynecol. 1986 Nov;155(5):1097-102 [3465243.001]
  • [Cites] Biometrics. 1988 Sep;44(3):837-45 [3203132.001]
  • [Cites] Gynecol Oncol. 1994 Sep;54(3):292-7 [8088605.001]
  • [Cites] Gynecol Oncol. 1994 Sep;54(3):321-6 [8088608.001]
  • [Cites] Am J Obstet Gynecol. 1996 Apr;174(4):1316-9 [8623863.001]
  • [Cites] Gynecol Oncol. 1997 Jan;64(1):141-6 [8995563.001]
  • [Cites] J Clin Pathol. 1996 Dec;49(12):967-70 [9038731.001]
  • [Cites] Gynecol Oncol. 1997 May;65(2):291-6 [9159340.001]
  • [Cites] Obstet Gynecol. 1997 Sep;90(3):441-7 [9277659.001]
  • [Cites] Cancer Detect Prev. 1999;23(5):397-400 [10468891.001]
  • [Cites] Eur J Gynaecol Oncol. 1999;20(4):315-7 [10475131.001]
  • [Cites] J Reprod Med. 2005 Aug;50(8):585-90 [16220763.001]
  • [Cites] Gynecol Oncol. 2008 Feb;108(2):402-8 [18061248.001]
  • [Cites] Int J Gynecol Cancer. 2002 Jul-Aug;12(4):372-5 [12144685.001]
  • (PMID = 18495222.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA083639; United States / NCI NIH HHS / CA / P50 CA083639; United States / NCI NIH HHS / CA / P50 CA098258; United States / NCI NIH HHS / CA / P50 CA098258
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Tumor-Associated, Carbohydrate; 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / CA-72-4 antigen; 0 / DEFB126 protein, human; 0 / Epididymal Secretory Proteins; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / beta-Defensins; 0 / mesothelin
  • [Other-IDs] NLM/ NIHMS243878; NLM/ PMC3594093
  •  go-up   go-down


70. Kumar VJ, Nin CY, Kuei LY, Tan KH, Yeo R, Lam PY: Survival and disease relapse in surgical stage I endometrioid adenocarcinoma of the uterus after adjuvant vaginal vault brachytherapy. Int J Gynecol Cancer; 2010 May;20(4):564-9
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival and disease relapse in surgical stage I endometrioid adenocarcinoma of the uterus after adjuvant vaginal vault brachytherapy.
  • INTRODUCTION: Advanced age, deep myoinvasion, whole cavity or lower uterine segment tumors, poor differentiation, and lymphovascular space invasion are known to increase recurrence risk and adversely affect survival in stage I endometrioid adenocarcinoma of the uterus.
  • METHODS: Data of 162 patients with surgical stage I endometrioid adenocarcinoma of the uterus with an increased risk of recurrence were reviewed from the year 1997 to 2008 at KK Gynaecological Cancer Centre, Singapore.
  • Most patients (54.3%) had surgical stage IC endometrioid adenocarcinoma, whereas the rest had stage IB.
  • Age, lymphovascular space invasion, and tumor volume and location were not significant parameters in surgical stage I endometrioid adenocarcinoma patients who failed.
  • The median survival for recurrent endometrial cancer was 5 years.
  • [MeSH-major] Brachytherapy. Carcinoma, Endometrioid / mortality. Endometrial Neoplasms / mortality. Neoplasm Recurrence, Local / mortality. Radiotherapy, Adjuvant / mortality. Uterine Neoplasms / mortality

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20686374.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


71. Montalto SA, Hakmi A, Moth P, Raju KS, Coutts M, Papadopoulos AJ, Devaja O: Well differentiated endometrioid adenocarcinoma of the uterus: a cancer unit or centre case? Eur J Gynaecol Oncol; 2009;30(1):35-9
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Well differentiated endometrioid adenocarcinoma of the uterus: a cancer unit or centre case?
  • OBJECTIVE: The purpose of this study was to investigate what proportion of cases showing a well differentiated endometrioid endometrial adenocarcinoma in the hysterectomy specimen removed at two UK cancer centres had adverse pathological features or advanced stage disease at the time of presentation.
  • STUDY DESIGN: Ninety-eight patients who were operated on at either the South East London Cancer Centre, London or the Kent Oncology Centre, Maidstone had a histological diagnosis of well differentiated (grade 1) endometrioid adenocarcinoma in their hysterectomy specimen.
  • RESULTS: Of the initial 98 cases, 65 patients (66.3%) were referred with a preoperative curettage showing a well differentiated endometrioid adenocarcinoma, 25 cases (25.5%) were referred with atypical endometrial hyperplasia, seven patients (7.1%) were referred with a moderately differentiated endometrioid adenocarcinoma, and one case (1.0%) was referred with a possible malignant mixed Mullerian tumour.
  • Subsequent histological examination of the hysterectomy specimens revealed that all of these cases had a well differentiated endometrioid adenocarcinoma.
  • From our study, 33.6% of cases with a well differentiated endometrioid adenocarcinoma of the uterus were Stage Ic or more at the time of presentation; 12.2% were at least FIGO Stage Ic, eight patients (8.2%) were FIGO Stage IIa, seven patients (7.1%) were Stage IIb and six patients (6.1%) were Stage III.
  • Cases with a preoperative biopsy showing atypical hyperplasia or well differentiated adenocarcinoma should have a preoperative MRI scan or preferably an intraoperative frozen section examination to identify those cases with adverse pathological features which need to be fully staged with pelvic and paraaortic lymphadenectomy.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Uterine Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19317254.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Italy
  •  go-up   go-down


72. Wicherek L, Popiela TJ, Galazka K, Dutsch-Wicherek M, Opławski M, Basta A, Klimek M: Metallothionein and RCAS1 expression in comparison to immunological cells activity in endometriosis, endometrial adenocarcinoma and endometrium according to menstrual cycle changes. Gynecol Oncol; 2005 Dec;99(3):622-30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metallothionein and RCAS1 expression in comparison to immunological cells activity in endometriosis, endometrial adenocarcinoma and endometrium according to menstrual cycle changes.
  • OBJECTIVE: Endometrium is a specialized organ in which phenomena controlling the level of cell proliferation and apoptosis are marked.
  • The aim of our study was to determine the presence of proteins involved in apoptosis and proliferation: RCAS1, MT and the number of CD56-positive cells and their activity to elucidate their possible role in the development of adenocarcinoma and endometriosis.
  • RESULTS: We found that endometrium during secretory menstrual cycle phase is characterized by significantly higher RCAS1 and higher MT expression than in proliferative phase.
  • Endometrial adenocarcinoma was characterized by significantly increased RCAS1 expression, while MT expression was comparable to the level found in the secretory phase.
  • CONCLUSIONS: The ability of endometrium to determine cytotoxic activity (RCAS1 expression changes) and high protection against DNA damage (MT expression) with concomitant changes in the number of immune cells and their activity, observed in normal endometrium during the menstrual cycle phases seems to be fundamental for pathological features of endometrial adenocarcinoma and endometriosis.
  • [MeSH-major] Adenocarcinoma / immunology. Antigens, Neoplasm / biosynthesis. Endometrial Neoplasms / immunology. Endometriosis / immunology. Endometrium / immunology. Menstrual Cycle / immunology. Metallothionein / biosynthesis

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16112719.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD56; 0 / Antigens, Differentiation, T-Lymphocyte; 0 / Antigens, Neoplasm; 0 / CD69 antigen; 0 / EBAG9 protein, human; 0 / Lectins, C-Type; 9038-94-2 / Metallothionein
  •  go-up   go-down


73. Francz M: [The premalignant disease of the endometrium: endometrial intraepithelial neoplasia]. Magy Onkol; 2008 Mar;52(1):35-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The premalignant disease of the endometrium: endometrial intraepithelial neoplasia].
  • [Transliterated title] Az endometrium rákmegelozo állapota: endometrialis intraepithelialis neoplasia.
  • The WHO 1994 classification for endometrial hyperplasias is based on the morphologic features of the lesions.
  • Although the predictive value of the atypical category is high, there are many typical hyperplasia cases with cancer progression.
  • Modern molecular data related to endometrial tumorigenesis and precise computerized morphometric analysis have identified the lesion that may be considered as a precursor of endometrioid adenocarcinoma.
  • By definition, this endometrial intraepithelial neoplasia (EIN) is a clonal proliferation of architecturally and cytologically altered endometrial glands which are prone to malignant transformation to endometrioid (type I) endometrial adenocarcinoma.
  • The morphometric basis of EIN diagnosis is the D-score (DS), which is a logical combination of three morphometric features that represent the glandular complexity, glandular volume and cytological alterations.
  • Hyperplasia cases that do not fit into the EIN categories are considered as benign or hormonal endometrial hyperplasia.
  • This is the theoretical basis of a new classification system in premalignant endometrial diseases.
  • [MeSH-major] Endometrial Neoplasms / diagnosis. Endometrium / pathology. Precancerous Conditions / classification

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18403295.001).
  • [ISSN] 0025-0244
  • [Journal-full-title] Magyar onkologia
  • [ISO-abbreviation] Magy Onkol
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.1.3.67 / PTEN Phosphohydrolase
  • [Number-of-references] 19
  •  go-up   go-down


74. Sánchez Anguiano LF, Puente Ledesma L, Lares Bayona EF, Milla Villeda RH: [Estrogenic receptors in hyperplasia and endometrial adenocarcinoma: immunohystochemical study with image analysis]. Ginecol Obstet Mex; 2007 Sep;75(9):501-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Estrogenic receptors in hyperplasia and endometrial adenocarcinoma: immunohystochemical study with image analysis].
  • [Transliterated title] Receptores de estrógenos en la hiperplasia y el adenocarcinoma de endometrio: estudio inmunohistoquímico con análisis de imagen.
  • BACKGROUND: The endometrium is a very dynamic organ that experience several half-full processes by the ovarian secretion of estradiol and progesterone.
  • The effect of hormones steroids, in the epithelial cells, endoteliales and estromales of the endometrium, is influenced by receptors of estrogens and progesterone.
  • OBJECTIVE: determine if there are any differences in the density of the estrogen receptors (ER) between the normal endometrial, the simple and complex hyperplasia, the atypical hyperplasia and the.
  • We included 143 samples that were knit together in 5 categories of the following way: Normal endometrial (n = 38), Simple hyperplasia (n = 58), Complex hyperplasia (n = 22), Atypical hyperplasia (n = 9), Adenocarcinoma (n = 16).
  • RESULTS: there were no statistical significant differences on the cell density with ER between the normal endometrial and the simple and complex hyperplasia.
  • The estrogen receptors are decreased in the atypical hyperplasia and the endometrial adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / chemistry. Endometrial Neoplasms / chemistry. Receptors, Estrogen / analysis
  • [MeSH-minor] Endometrial Hyperplasia. Female. Humans. Immunohistochemistry. Middle Aged. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18293624.001).
  • [ISSN] 0300-9041
  • [Journal-full-title] Ginecología y obstetricia de México
  • [ISO-abbreviation] Ginecol Obstet Mex
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Mexico
  • [Chemical-registry-number] 0 / Receptors, Estrogen
  •  go-up   go-down


75. Nabli H, Tuller E, Sharpe-Timms KL: Haptoglobin expression in endometrioid adenocarcinoma of the uterus. Reprod Sci; 2010 Jan;17(1):47-55
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Haptoglobin expression in endometrioid adenocarcinoma of the uterus.
  • OBJECTIVE: Elevated serum haptoglobin (Hp) concentrations have been reported in patients with malignant diseases.
  • We have shown that Hp is produced by and localizes only in the stroma and not the epithelium of endometriotic lesions, which share many characteristics of carcinoma.
  • Furthermore, Hp mRNA and protein are found exclusively in the stroma of eutopic endometrium from women with endometriosis and not those without endometriosis.
  • We hypothesized that characteristic patterns of Hp gene expression and protein localization in endometrioid adenocarcinoma of the uterus may provide insight into the clinical utility of Hp as a tumor marker or alternative therapeutic approach.
  • METHODS: Biopsies of endometrioid adenocarcinoma tumors of the uterus and their adjacent nonaffected endometrium were collected.
  • Normal endometrium was collected from healthy women.
  • RESULTS: Haptoglobin mRNA levels were significantly greater (P < .005) in endometrioid adenocarcinoma and adjacent nonaffected endometrial tissues than normal endometrium.
  • No correlation was found between Hp levels and cancer stage (P = .673) or grade (P = .739).
  • Haptoglobin protein localized in both stromal and glandular epithelial cells of endometrioid adenocarcinoma and their adjacent nonaffected tissue but not in control endometrium.
  • CONCLUSIONS: Our results have identified, for the first time, unique patterns of Hp mRNA expression and protein localization in the stromal and glandular epithelial cells of endometrioid adenocarcinoma of the uterus.
  • We propose that this unique pattern of endometrioid adenocarcinoma Hp expression may be developed as a novel diagnostic marker.
  • Modulation of Hp, with its immunomodulatory and angiogenic properties, may generate novel methods of prevention or treatment for endometrial cancer.
  • [MeSH-major] Carcinoma, Endometrioid / metabolism. Endometrial Neoplasms / metabolism. Haptoglobins / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19801537.001).
  • [ISSN] 1933-7205
  • [Journal-full-title] Reproductive sciences (Thousand Oaks, Calif.)
  • [ISO-abbreviation] Reprod Sci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Haptoglobins; 0 / RNA, Messenger
  •  go-up   go-down


76. Goldman NA, Katz EB, Glenn AS, Weldon RH, Jones JG, Lynch U, Fezzari MJ, Runowicz CD, Goldberg GL, Charron MJ: GLUT1 and GLUT8 in endometrium and endometrial adenocarcinoma. Mod Pathol; 2006 Nov;19(11):1429-36
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] GLUT1 and GLUT8 in endometrium and endometrial adenocarcinoma.
  • Regulation of glucose transport facilitator expression has been demonstrated in endometrial tissue and endometrial adenocarcinoma.
  • The following experiments were conducted to quantify and localize the expression of GLUT1 and GLUT8 in benign endometrium and compare this expression to endometrial cancer.
  • Endometrial tissue samples were obtained from random hysterectomy specimens of patients with benign indications for surgery and endometrial cancer.
  • Endometrial samples from 65 women who had undergone hysterectomy were examined (n=38 benign, n=27 malignant).
  • A 44 and a 35.4 kDa immunoreacive species was demonstrated in endometrium and endometrial cancer for GLUT1 and GLUT8, respectively.
  • GLUT8 expression was increased in all tumor subtypes compared to atrophic endometrium (P<0.001).
  • Apical localization by GLUT1 and GLUT8 was demonstrated in endometrial glands.
  • GLUT1 and GLUT8 demonstrated diffuse intracellular localization in the cancer subtypes.
  • GLUT1 and GLUT8 are expressed in both human endometrium and endometrial cancer.
  • [MeSH-major] Adenocarcinoma / chemistry. Biomarkers, Tumor / analysis. Endometrial Neoplasms / chemistry. Endometrium / chemistry. Glucose Transport Proteins, Facilitative / analysis. Glucose Transporter Type 1 / analysis

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16892013.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / DK47425; United States / NHLBI NIH HHS / HL / HL58119
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glucose Transport Proteins, Facilitative; 0 / Glucose Transporter Type 1; 0 / SLC2A1 protein, human; 0 / SLC2A8 protein, human
  •  go-up   go-down


77. Xiaoxin M, Yingnan J, Yanxia L, Shu L, Yuanqi H, Hongwei L: Experimental research on the depressant effect of aspirin on Ishikawa adenocarcinoma endometrium cell growth. Int J Gynecol Cancer; 2009 Oct;19(7):1182-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Experimental research on the depressant effect of aspirin on Ishikawa adenocarcinoma endometrium cell growth.
  • OBJECTIVE: : To investigate the effect of aspirin on human Ishikawa adenocarcinoma endometrium cell proliferation and apoptosis and its related mechanism through in vitro experiments.
  • METHODS: : The effects on Ishikawa adenocarcinoma endometrium cell proliferation and cell cycle of aspirin at different intervals and concentrations were determined with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide method and flow cytometry; cell morphous change after the effect of aspirin was observed with transmission electron microscope; and the effect of aspirin on B-cell lymphoma/leukemia-x, long (Bcl-xl) proteinum expression was determined with Western blot.
  • RESULTS: : Aspirin had a significant depressant effect on human Ishikawa adenocarcinoma endometrium cell proliferation, and the effect showed time and dose dependence (P < 0.05).
  • CONCLUSIONS: : Aspirin has a distinct depressant effect on human Ishikawa adenocarcinoma endometrium cell growth, and its effect may be realized by lowering Bcl-xl proteinum expression.
  • [MeSH-major] Adenocarcinoma / pathology. Aspirin / pharmacology. Cell Line, Tumor. Cell Proliferation / drug effects. Endometrial Neoplasms / pathology

  • Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19820387.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCL2L1 protein, human; 0 / bcl-X Protein; R16CO5Y76E / Aspirin
  •  go-up   go-down


78. Donoghue JF, Lederman FL, Susil BJ, Rogers PA: Lymphangiogenesis of normal endometrium and endometrial adenocarcinoma. Hum Reprod; 2007 Jun;22(6):1705-13
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphangiogenesis of normal endometrium and endometrial adenocarcinoma.
  • BACKGROUND: Information about lymphatics and lymphangiogenesis in the human endometrium is limited.
  • We investigated the distribution of endometrial lymphatic vessels during the normal menstrual cycle and in association with endometrial adenocarcinoma and investigated the expression of lymphangiogenic growth factors, vascular endothelial growth factor (VEGF)-C, VEGF-D and VEGF receptor-3 (VEGF-R3).
  • METHODS AND RESULTS: Full thickness uterine samples (n = 23 proliferative; n = 23 secretory) and endometrial adenocarcinoma samples (n = 7 grade I; n = 10 grade III) were collected for the study and analysed by immunohistochemistry and western blotting.
  • Lymphatic vessels of endometrial adenocarcinomas were located intra-tumoural and peri-tumoural with significant increases in the peri-tumoural lymphatic vessels compared with normal basalis (P = 0.02).
  • Interestingly, high-grade adenocarcinoma vessels containing tumour emboli demonstrated a mixed blood/lymphatic endothelial cell phenotype.
  • VEGF-C and VEGF-D were immunolocalized in glandular epithelium and some stromal cells with the staining intensity of this localization increasing in endometrial adenocarcinoma.
  • Protein analysis identified VEGF-C (58, 41, 31 and 21 kD) and VEGF-D (56, 41, 31 and 21 kD) and VEGF-R3 (148 and 65 kD) peptides in normal endometrium, with significant increases in several of these peptides for VEGF-C and VEGF-D and no changes in protein expression for VEGF-R3 in endometrial adenocarcinoma.
  • CONCLUSION: Endometrial lymphatics are significantly reduced in the functionalis, and increases in endometrial adenocarcinoma peri-tumoural lymphatics are associated with increases in VEGF-C and VEGF-D peptides.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology. Endometrium / anatomy & histology. Lymphangiogenesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17347164.001).
  • [ISSN] 0268-1161
  • [Journal-full-title] Human reproduction (Oxford, England)
  • [ISO-abbreviation] Hum. Reprod.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Vascular Endothelial Growth Factor C; 0 / Vascular Endothelial Growth Factor D; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-3
  •  go-up   go-down


79. Saito M, Sato Y, Watanabe J, Kuramoto H, Kaba S, Fukuda T: Angiogenic factors in normal endometrium and endometrial adenocarcinoma. Pathol Int; 2007 Mar;57(3):140-7
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angiogenic factors in normal endometrium and endometrial adenocarcinoma.
  • In the endometrium, angiogenesis plays important roles not only in tumor growth but also in the menstrual cycle.
  • The purpose of the present paper was to investigate immunohistochemically the correlation between angiogenic factor expression and angiogenic score in normal and neoplastic endometrium.
  • Immunohistochemical staining for vascular endothelial growth factor (VEGF), angiopoietin (Ang)-1, Ang2, Tie2, CD34 and CD105 was performed on formalin-fixed and paraffin-embedded tissues from 31 normal endometrium and 85 endometrial adenocarcinoma.
  • The levels of each angiogenic factor were different in the phases of the menstrual cycle and each layer of normal endometrium.
  • In general, VEGF and Tie2 expression was higher in adenocarcinoma than in normal epithelial cells.
  • Conversely, Ang1 and Ang2 expression was higher in normal epithelium than in adenocarcinoma.
  • The angiogenic score (CD105/CD34) tended to be higher in the adenocarcinoma than in the normal epithelium.
  • It is suggested that the angiogenic pathway and the role of these factors seem to differ between normal tissue and carcinoma of the endometrium.
  • [MeSH-major] Adenocarcinoma / metabolism. Angiogenesis Inducing Agents / metabolism. Endometrial Neoplasms / metabolism. Endometrium / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17295646.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / ANGPT1 protein, human; 0 / Angiogenesis Inducing Agents; 0 / Angiopoietin-1; 0 / Angiopoietin-2; 0 / Antigens, CD; 0 / Antigens, CD34; 0 / Biomarkers, Tumor; 0 / ENG protein, human; 0 / Receptors, Cell Surface; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Receptor, TIE-2
  •  go-up   go-down


80. Nishimura N, Hachisuga T, Yokoyama M, Iwasaka T, Kawarabayashi T: Clinicopathologic analysis of the prognostic factors in women with coexistence of endometrioid adenocarcinoma in the endometrium and ovary. J Obstet Gynaecol Res; 2005 Apr;31(2):120-6
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic analysis of the prognostic factors in women with coexistence of endometrioid adenocarcinoma in the endometrium and ovary.
  • AIM: To compare the survival and prognostic factors of patients with dual primary ovarian and endometrial cancers (primary group), and endometrial cancers metastatic to the ovaries (metastatic group).
  • METHODS: Thirty-six patients with gross tumors confined to the pelvis and of endometrioid adenocarcinoma subtype in both the endometrium and ovary were selected from our file of 546 Japanese women with endometrial carcinoma.
  • Univariate analyses showed that older age (P < 0.05) and the presence of lymphovascular space invasion (LVSI; P < 0.004) of the tumor of the uterus were significantly associated with a poor prognosis in the metastatic group.
  • CONCLUSION: When encountering women with coexisting endometrioid carcinoma in the endometrium and ovary with gross tumor limited to the pelvis, more attention should be paid to LVSI of the tumor of the uterus as a poor prognostic indicator.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / pathology. Ovarian Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15771637.001).
  • [ISSN] 1341-8076
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


81. Wallace AE, Gibson DA, Saunders PT, Jabbour HN: Inflammatory events in endometrial adenocarcinoma. J Endocrinol; 2010 Aug;206(2):141-57
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inflammatory events in endometrial adenocarcinoma.
  • Endometrial adenocarcinoma is the most common gynaecological malignancy in western countries.
  • Many of the established risk factors for developing endometrial cancer are associated with excess exposure to oestrogen unopposed by progesterone.
  • However, a number of risk factors also promote inflammation, another feature proposed to influence cancer development.
  • The human cycling endometrium undergoes regular and cyclical episodes of inflammation.
  • Moreover, hormonal and genetic changes that occur early in the development of endometrial adenocarcinoma can exacerbate the local inflammatory environment.
  • Via alterations in the expression of local mediators and immune cell function, these may contribute to the development of endometrial cancer.
  • This review discusses the contribution of inflammation to the initiation and progression of endometrial adenocarcinoma.
  • Manipulation of inflammatory pathways may therefore represent a therapeutic target in endometrial adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology. Inflammation

  • Hazardous Substances Data Bank. PROGESTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20406782.001).
  • [ISSN] 1479-6805
  • [Journal-full-title] The Journal of endocrinology
  • [ISO-abbreviation] J. Endocrinol.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U127685844; United Kingdom / Medical Research Council / / MC/ U127684438; United Kingdom / Medical Research Council / / U.1276.00.004.00002.01; United Kingdom / Medical Research Council / / U.1276.00.002.00005.01 (85844); United Kingdom / Medical Research Council / / U1276.00.002.00005.01
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Androgens; 0 / Chemokines; 0 / Cytokines; 0 / Estrogens; 0 / Glucocorticoids; 0 / KRAS protein, human; 0 / NF-kappa B; 0 / Prostaglandins; 0 / Proto-Oncogene Proteins; 4G7DS2Q64Y / Progesterone; EC 3.1.3.67 / PTEN Phosphohydrolase; EC 3.1.3.67 / PTEN protein, human; EC 3.6.5.2 / Proto-Oncogene Proteins p21(ras); EC 3.6.5.2 / ras Proteins
  • [Number-of-references] 190
  •  go-up   go-down


82. Cirpan T, Terek MC, Mgoyi L, Zekioglu O, Iscan O, Ozsaran A: Immunohistochemical evaluation of PTEN protein in patients with endometrial intraepithelial neoplasia compared to endometrial adenocarcinoma and proliferative phase endometrium. Eur J Gynaecol Oncol; 2006;27(4):389-92
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical evaluation of PTEN protein in patients with endometrial intraepithelial neoplasia compared to endometrial adenocarcinoma and proliferative phase endometrium.
  • OBJECTIVE: The aim of this study was to reclassify endometrial hyperplasia cases and examine PTEN protein immunoreactivity compared to cases with endometrial adenocarcinoma and proliferative endometrium.
  • DESIGN: Endometrial samples from 37 women with endometrial hyperplasia with atypia were reclassified as endometrial intraepithelial neoplasia (EIN).
  • Eighteen were complex and 19 were simple endometrial hyperplasia.
  • Twenty-our cases of EIN, ten endometrial adenocarcinoma cases and ten proliferative phase endometrium sections were immunostained for PTEN expression.
  • RESULTS: Twenty-four of 37 (64%) women with endometrial hyperplasia were reclassified as EIN.
  • There were no difference in PTEN immunoreactivity between EIN, endometrial adenocarcinoma and endometrial proliferation (p = 0.342).
  • PTEN immunoreactivity was partially lost in seven and present in three of the patients with endometrial adenocarcinoma.
  • CONCLUSION: EIN classification may provide a better and more objective assessment of endometrial hyperplasia cases.
  • PTEN expression showed no differences among the cases of EIN, endometrial carcinoma and proliferative phase endometrium.
  • [MeSH-major] Adenocarcinoma / metabolism. Cell Proliferation. Endometrial Hyperplasia / metabolism. Endometrial Neoplasms / metabolism. Endometrium / metabolism. PTEN Phosphohydrolase / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17009632.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


83. Pervatikar SK, Rao R, Dinesh US: Ossifying luteinized thecoma of the ovary with endometrial adenocarcinoma. Indian J Pathol Microbiol; 2009 Apr-Jun;52(2):222-4
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ossifying luteinized thecoma of the ovary with endometrial adenocarcinoma.
  • We report a case of a 66-year-old post-menopausal female with the chief complaint of uterine bleeding of 7 months duration.
  • Endometrial curettage performed showed features of endometrial adenocarcinoma.
  • This case is the second in the literature of osseous metaplasia in an ovarian luteinized thecoma, with the association of endometrial adenocarcinoma suggesting its functional status.
  • [MeSH-major] Adenocarcinoma / complications. Adenocarcinoma / diagnosis. Ovarian Neoplasms / pathology. Thecoma / complications. Thecoma / diagnosis. Uterine Neoplasms / pathology
  • [MeSH-minor] Aged. Endometrium / pathology. Female. Humans. Hysterectomy. Luteinization. Ossification, Heterotopic. Ovary / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19332920.001).
  • [ISSN] 0974-5130
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


84. Kilic G, Gurates B, Garon J, Kang H, Arun B, Lampley CE, Kurzel R, Ashfaq R: Expression of cyclooxygenase-2 in endometrial adenocarcinoma. Eur J Gynaecol Oncol; 2005;26(3):271-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of cyclooxygenase-2 in endometrial adenocarcinoma.
  • Studies have shown that COX-2 is up-regulated in several epithelial carcinomas.
  • In this study, we wish to elucidate if endometrial cyclooxygenase-2 (COX-2) expression in endometrial adenocarcinoma is increased relative to normal endometrium.
  • Thirty-six deparaffinized tissue sections from patients with endometrial adenocarcinoma were analyzed by immunohistochemistry for the presence of COX-2.
  • A control group consisted of 13 age-matched patients without malignancy, who underwent surgery for uterine prolapse.
  • We found that COX-2 expression was markedly increased in 13 of 36 patients (36.1%) with endometrial adenocarcinoma: in contrast only one of 13 (7.7%) control patients demonstrated increased COX-2 expression (p < or = 0.05).
  • Eight of the 13 COX-2 positive patients in the study had well differentiated adenocarcinoma; the remaining five COX-2 positive patients had moderately and poorly differentiated adenocarcinoma (4 and 1, respectively).
  • In conclusion, COX-2 expression in the endometrium is associated with endometrial adenocarcinoma, especially of the well differentiated type.
  • This may provide an avenue for chemoprevention of endometrial adenocarcinoma.
  • In addition, with new selective inhibitory drugs being developed, inhibition of COX-2 may play an adjunctive role approach to standard therapy, especially for well-differentiated endometrial carcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Endometrial Neoplasms / metabolism. Prostaglandin-Endoperoxide Synthases / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15991524.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Membrane Proteins; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases
  •  go-up   go-down


85. Tantbirojn P, Triratanachat S, Trivijitsilp P, Niruthisard S: Comparison between adenocarcinoma in both endocervical and endometrial specimens from fractional curettage and pathologic findings in subsequent hysterectomy specimens. J Med Assoc Thai; 2008 Sep;91(9):1313-7
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison between adenocarcinoma in both endocervical and endometrial specimens from fractional curettage and pathologic findings in subsequent hysterectomy specimens.
  • OBJECTIVE: To evaluate the hysterectomy specimen findings in the patients who underwent fractional curettage (F&C) with presence of adenocarcinoma in both endocervical and endometrial specimens.
  • MATERIAL AND METHOD: Forty-one patients who had adenocarcinoma in both endocervical and endometrial specimens from F&C and underwent subsequent hysterectomy for surgical staging without pre-operative radiotherapy or chemotherapy at King Chulalongkorn Memorial Hospital between 1999 and 2007 were evaluated Histologic slides from both F&C and hysterectomy specimens were reviewed and assessed All cases of endometrial adenocarcinoma with cervical involvement (stage 2) in hysterectomy specimens were also assessed and compared to the results in F&C specimens.
  • RESULTS: Fifteen patients (36.6%) with both positive endocervical and endometrial specimens from F&C were diagnosed as endometrial adenocarcinoma within uterine cavity with lower uterine segment involvement.
  • Only 34.1% of cases were endometrial carcinomas with cervical involvement.
  • In the 35 cases with endometrial carcinoma stage 2, 60% had adenocarcinoma in both endocervical and endometrial specimens from F&C.
  • CONCLUSION: In the patients who had adenocarcinoma in both endocervical and endometrial specimens from fractional curettage, the most common final pathological diagnosis from hysterectomy specimens was endometrial adenocarcinoma within uterine cavity with lower uterine segment involvement.
  • Therefore, only 60% of endometrial carcinoma stage 2 revealed positive adenocarcinoma in both endocervical and endometrial specimens from fractional curettage.
  • [MeSH-major] Adenocarcinoma / pathology. Cervix Uteri / pathology. Dilatation and Curettage. Endometrial Neoplasms / pathology. Endometrium / pathology. Hysterectomy

  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18843857.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


86. Boutet G: [Levonorgestrel-releasing intrauterine device (Mirena) and breast cancer: what do we learn from literature for clinical practice?]. Gynecol Obstet Fertil; 2006 Nov;34(11):1015-23
Hazardous Substances Data Bank. LEVONORGESTREL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Levonorgestrel-releasing intrauterine device (Mirena) and breast cancer: what do we learn from literature for clinical practice?].
  • [Transliterated title] Dispositif intra-utérin au lévonorgestrel (Mirena) et cancer du sein: que nous apporte la littérature pour la pratique quotidienne?
  • Annual occurrence of breast cancer is constantly increasing in France.
  • In 2000, the number of breast cancer cases for women of 30-49 years was estimated at 9,918, which represents 23.7% of all breast cancer cases diagnosed that year.
  • Because contraception is an important matter for women whose ovarian function survived cancer treatments, the question of whether to use such device on a woman with breast cancer has become a frequent and controversial gynaecological issue.
  • First, whether the use of IUD LNG increases the risk of breast cancer: there is at the moment no "A" level answer available.
  • Second, whether the use of IUD LNG counterbalances the endometrial effects of Tamoxifene: based on a limited level of evidence via a single randomised controlled trial on a small number of patients for one year only, this device appears to be able to prevent benign endometrial modifications.
  • However, there is no conclusive study regarding its effectiveness on the prevention of endometrium adenocarcinoma caused by Tamoxifene.
  • Third, whether a woman with a personal antecedent of breast cancer can safely use DIU LNG: it is necessary to remove it promptly upon suspicion or diagnosis, to dissuade its use in case of current cancer, and, in the event of cancer remission for more than 5 years, to generally avoid this contraceptive method except on a case by case basis and with a regular medical follow-up.
  • [MeSH-minor] Adenocarcinoma / prevention & control. Adult. Antineoplastic Agents, Hormonal / therapeutic use. Endometrial Neoplasms / prevention & control. Evidence-Based Medicine. Female. France / epidemiology. Humans. Middle Aged. Tamoxifen / therapeutic use

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17092752.001).
  • [ISSN] 1297-9589
  • [Journal-full-title] Gynécologie, obstétrique & fertilité
  • [ISO-abbreviation] Gynecol Obstet Fertil
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Contraceptive Agents, Female; 094ZI81Y45 / Tamoxifen; 5W7SIA7YZW / Levonorgestrel
  • [Number-of-references] 59
  •  go-up   go-down


87. Gil da Costa RM, Santos M, Amorim I, Lopes C, Pereira PD, Faustino AM: An immunohistochemical study of feline endometrial adenocarcinoma. J Comp Pathol; 2009 May;140(4):254-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An immunohistochemical study of feline endometrial adenocarcinoma.
  • Feline endometrial adenocarcinomas are uncommon malignant neoplasms that have to date been poorly characterized.
  • The present immunohistochemical study describes the expression of the pancytokeratins AE1 and AE3, cytokeratin-14, vimentin, alpha-actin, cyclo-oxygenase-2, E-cadherin, beta-catenin, the progesterone receptor, the oestrogen receptor and caveolin-1 within normal feline uterine tissue and tissue from six cats with endometrial adenocarcinoma.
  • Synthesis of cyclo-oxygenase-2 and reduced expression of progesterone receptors may be involved in the neoplastic transformation of feline endometrium.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / veterinary. Cat Diseases / metabolism. Endometrial Neoplasms / metabolism. Endometrial Neoplasms / veterinary. Immunohistochemistry / veterinary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19201419.001).
  • [ISSN] 1532-3129
  • [Journal-full-title] Journal of comparative pathology
  • [ISO-abbreviation] J. Comp. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


88. Schmidt T, Breidenbach M, Nawroth F, Mallmann P, Beyer IM, Fleisch MC, Rein DT: Hysteroscopy for asymptomatic postmenopausal women with sonographically thickened endometrium. Maturitas; 2009 Feb 20;62(2):176-8
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hysteroscopy for asymptomatic postmenopausal women with sonographically thickened endometrium.
  • Endometrial carcinoma is the most common genital cancer in women.
  • Endometrial thickness (double layer) is measured by transvaginal sonography and thickening indicates an increased risk of malignancy or other pathology (hyperplasia or polyps).
  • OBJECTIVE: We sought to correlate hysteroscopic and pathological findings in asymptomatic postmenopausal women with sonographically thickened endometrium (>6mm).
  • STUDY DESIGN: A prospective observational study in a university hospital of 304 postmenopausal women referred between 1996 and 2006 because of a sonographically thickened endometrium in the absence of abnormal bleeding, who underwent continuous flow hysteroscopy (4.5mm Storz hysteroscope) and fractionated curettage of the uterine cervix and corpus (D & C) in addition to vaginal sonography (5MHz probe).
  • Average endometrial thickness measured by ultrasound was 12mm+/-6.7mm.
  • Hysteroscopy suggested the presence of endometrial polyps in 226 women (74.3%), simple endometrial hyperplasia in 34 (11.2%), atrophic endometrium in 18 (5.9%), complex endometrial hyperplasia in 2 (0.7%), atypical hyperplasia in 3 (1%) and leiomyoma in 9 (3.0%).
  • In 12 women (3.9%), the hysteroscopic appearance suggested malignancy and histology revealed endometrial adenocarcinoma.
  • CONCLUSION: Hysteroscopy represents an easy, safe and effective method for the investigation of asymptomatic women with a thickened endometrium found with transvaginal ultrasound.
  • The commonest pathology was endometrial polyps.
  • [MeSH-major] Endometrial Hyperplasia / diagnosis. Endometrial Neoplasms / diagnosis. Hysteroscopy. Uterine Neoplasms / diagnosis
  • [MeSH-minor] Aged. Atrophy / diagnosis. Endometrium / pathology. Endometrium / ultrasonography. Female. Humans. Leiomyoma / diagnosis. Middle Aged. Polyps / diagnosis. Postmenopause. Prospective Studies. Risk Factors. Uterine Diseases / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19121901.001).
  • [ISSN] 0378-5122
  • [Journal-full-title] Maturitas
  • [ISO-abbreviation] Maturitas
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


89. Yang X, Dong Y, Zhao J, Sun H, Deng Y, Fan J, Yan Q: Increased expression of human macrophage metalloelastase (MMP-12) is associated with the invasion of endometrial adenocarcinoma. Pathol Res Pract; 2007;203(7):499-505

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased expression of human macrophage metalloelastase (MMP-12) is associated with the invasion of endometrial adenocarcinoma.
  • To evaluate the association between the expression of human macrophage metalloelastase (matrix metalloproteinase-12, MMP-12) with cancer invasion and differentiation of endometrial adenocarcinoma, specimens from endometrial adenocarcinoma (n=61) of diverse stages and histologic types were collected from patients having undergone hysterectomy, and specimens from normal endometrium (n=38) were obtained from patients with benign diseases.
  • The positive rate of MMP-12 was significantly increased in endometrial adenocarcinoma (81.97%) as compared with that in normal endometrium (13.16%).
  • The results showed that expression of MMP-12 correlated with stage (p=0.022) and grade (p=0.018) of endometrial cancer.
  • MMP-12 immunoreactive proteins were found mainly on the glandular epithelial cells of endometrial adenocarcinoma.
  • The macrophage infiltration detected by CD68 immunohistochemical staining in endometrial adenocarcinoma was also higher than that in normal endometrium.
  • In this study, we show that in addition to macrophages, endometrial adenocarcinoma cells are able to express MMP-12.
  • Increased MMP-12 expression tended to be associated with the extent of adenocarcinoma invasion accompanied by marked macrophage infiltration.
  • Our results suggest that MMP-12 is an important oncogene in high-stage and high-grade endometrial adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Endometrial Neoplasms / metabolism. Matrix Metalloproteinase 12 / biosynthesis. Neoplasm Invasiveness / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17574772.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD68 antigen, human; EC 3.4.24.65 / Matrix Metalloproteinase 12
  •  go-up   go-down


90. Ozuysal S, Oztürk H, Bilgin T, Filiz G: Expression of cyclin D1 in normal, hyperplastic and neoplastic endometrium and its correlation with Ki-67 and clinicopathological variables. Arch Gynecol Obstet; 2005 Feb;271(2):123-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of cyclin D1 in normal, hyperplastic and neoplastic endometrium and its correlation with Ki-67 and clinicopathological variables.
  • METHODS: We investigated cyclin D1 expression in proliferative endometrium, endometrial hyperplasia and endometrioid adenocarcinoma, and examined the correlation of cyclin D1 expression with Ki67 as a cell proliferation associated marker.
  • Immunohistochemical expression of cyclin D1 and Ki67 were studied in 30 cases with endometrial carcinoma, 14 cases with atypical hyperplasia, 15 cases with simple hyperplasia and 30 cases with proliferative endometrium.
  • RESULTS: One out of 30 patients (3.3%) with proliferative endometrium, 1 out of 14 patients (7.1%) with atypical hyperplasia, and 8 out of 30 patients (26.6%) with endometrial carcinoma were found to have immunoreactivity to cyclin D1.
  • Statistically significant difference was found in cyclin D1 immunoreactivity between both proliferative endometrium and adenocarcinoma, and simple hyperplasia and adenocarcinoma (p<0.05).
  • In patients with adenocarcinoma, cyclin D1 immunoreactive cases had higher mean Ki67 values compared with the non-immunoreactive ones (p<0.05).
  • CONCLUSION: Cyclin D1 expression in endometrial carcinoma is higher than proliferative endometrium and simple hyperplasia.
  • These findings support that cyclin D1 may play a role in endometrial carcinogenesis.
  • [MeSH-major] Carcinoma, Endometrioid / metabolism. Cyclin D1 / biosynthesis. Endometrial Hyperplasia / metabolism. Endometrial Neoplasms / metabolism. Endometrium / metabolism

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14740230.001).
  • [ISSN] 0932-0067
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Ki-67 Antigen; 136601-57-5 / Cyclin D1
  •  go-up   go-down


91. Pianzola HM, Ottino A: ["Glassy - cell" like adenocarcinoma: a new variant of gastric tumor]. Acta Gastroenterol Latinoam; 2006 Dec;36(4):205-10
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ["Glassy - cell" like adenocarcinoma: a new variant of gastric tumor].
  • [Transliterated title] Adenocarcinoma de tipo glassy - cell: una nueva variante de tumor gástrico.
  • Most gastric malignancies correspond histologically to adenocarcinomas, either of the intestinal or diffuse type, other tumoral varieties being much less frequent.
  • We report a case of a malignant epithelial tumor, whose histological and cytological characteristics correspond to an unusual, although well defined entity, which may appear in the cervix and less frequently in the endometrium, known as adenocarcinoma of the glassy - cell variety.
  • [MeSH-major] Adenocarcinoma / pathology. Stomach Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Fatal Outcome. Gastrectomy. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17225449.001).
  • [ISSN] 0300-9033
  • [Journal-full-title] Acta gastroenterologica Latinoamericana
  • [ISO-abbreviation] Acta Gastroenterol. Latinoam.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Argentina
  •  go-up   go-down


92. de Góis Speck NM, Focchi J, Alves AC, Ribalta JC, Osório CA: Relationship between angiogenesis and grade of histologic differentiation in endometrial adenocarcinoma. Eur J Gynaecol Oncol; 2005;26(6):599-601

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship between angiogenesis and grade of histologic differentiation in endometrial adenocarcinoma.
  • The objective of the study was to quantify vessels and to relate them to the degree of histologic differentiation in endometrial adenocarcinoma.
  • We studied 35 cases of which ten were G1, 13 G2 and 12 G3 adenocarcinomas.
  • Mean vessel count was 15.3 for G1; 19 for G2 and 22.7 for G3 adenocarcinomas; in the control group it was 11.6 for atrophic and 13.2 for proliferative endometria.
  • Slightly differentiated adenocarcinoma presented greater angiogenesis than normal and well-differentiated carcinoma.
  • In contrast, moderately differentiated carcinoma showed greater angiogenicity as related to normal endometrium, but did not differ from other tumoral endometria.
  • [MeSH-major] Carcinoma, Endometrioid / blood supply. Endometrial Neoplasms / blood supply. Endometrium / blood supply. Neovascularization, Pathologic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16398216.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


93. Colling R, Lopes T, Das N, Mathew J: Endometrial metastasis of colorectal cancer with coincident endometrial adenocarcinoma. BMJ Case Rep; 2010;2010
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial metastasis of colorectal cancer with coincident endometrial adenocarcinoma.
  • Metastasis to the uterine corpus is uncommon and secondary colorectal tumours of the endometrium are rare.
  • We describe a uterine tumour with components of both primary endometrial and metastatic colorectal carcinomata.
  • She had an abdominoperineal resection 3 years previously for a Dukes stage B rectal carcinoma.
  • A transvaginal ultrasonography showed a thickened endometrium.
  • Histology immunophenotyping showed a CK7+, CK20+, CA125- and CEA+ colorectal metastasis (a profile consistent with her previous cancer) associated with a primary CK7+, CK20-, CA125+ and CEA- endometroid endometrial adenocarcinoma.
  • We conclude this represents endometrial metastasis of colorectal carcinoma with coincident primary endometrial adenocarcinoma.
  • We speculate as to whether the endometrial carcinoma arose de novo or was induced by the colorectal metastasis, or whether the primary endometrial tumour provided a fertile site for the colorectal metastasis.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / secondary. Carcinoma, Endometrioid / diagnosis. Colorectal Neoplasms / diagnosis. Colorectal Neoplasms / pathology. Endometrial Neoplasms / diagnosis. Endometrial Neoplasms / secondary. Neoplasms, Multiple Primary / diagnosis
  • [MeSH-minor] Aged. Biomarkers, Tumor / analysis. Diagnosis, Differential. Endometrium / pathology. Endosonography. Female. Humans. Image Interpretation, Computer-Assisted. Magnetic Resonance Imaging. Neoplasm Staging. Postoperative Complications / diagnosis. Postoperative Complications / pathology. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Endometrial cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 2000 Apr;13(4):379-88 [10786803.001]
  • [Cites] Eur J Gynaecol Oncol. 2001;22(2):122-6 [11446475.001]
  • [Cites] Int J Gynecol Pathol. 2002 Jan;21(1):11-5 [11781517.001]
  • [Cites] J Natl Cancer Inst. 2004 Feb 18;96(4):261-8 [14970275.001]
  • [Cites] Gynecol Oncol. 2004 Apr;93(1):252-6 [15047246.001]
  • [Cites] Cancer. 1982 Nov 15;50(10):2163-9 [7127256.001]
  • [Cites] Jpn J Surg. 1991 May;21(3):352-6 [1857041.001]
  • [Cites] Pathologe. 1993 Jan;14(1):58-60 [8451231.001]
  • [Cites] Tumori. 1995 Sep-Oct;81(5):383-6 [8804459.001]
  • [Cites] Hepatogastroenterology. 1999 Mar-Apr;46(26):981-2 [10370650.001]
  • [Cites] Dis Esophagus. 2005;18(2):124-6 [16053489.001]
  • [Cites] Int J Gynecol Pathol. 2006 Apr;25(2):101-20 [16633059.001]
  • [Cites] Surg Today. 2008;38(7):651-5 [18612793.001]
  • [Cites] APMIS. 2008 Jun;116(6):538-40 [18754330.001]
  • [Cites] Int J Surg Pathol. 2011 Dec;19(6):787-90 [19443868.001]
  • (PMID = 22791861.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC3028565
  •  go-up   go-down


94. Krepinska E, Kriz JT, Laco J: Endometroid adenocarcinoma of the uterus, borderline tumor of the ovary and Brenner tumor of the contralateral ovary in a 63-year-old woman. Eur J Gynaecol Oncol; 2010;31(5):584-5
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometroid adenocarcinoma of the uterus, borderline tumor of the ovary and Brenner tumor of the contralateral ovary in a 63-year-old woman.
  • Synchronous primary cancers of the endometrium and ovary occur in approximately 10% of all women with ovarian cancer and 5% of all women with endometrial cancer.
  • The pathogenesis of synchronous endometrial and ovarian cancer is unclear.
  • We report a case of unusual co-existence of endometroid adenocarcinoma of the uterus, serous borderline tumor of the ovary and Brenner tumor of the contralateral ovary in a 63-year-old woman.
  • [MeSH-major] Brenner Tumor / pathology. Carcinoma, Endometrioid / pathology. Cystadenocarcinoma, Serous / pathology. Endometrial Neoplasms / pathology. Neoplasms, Multiple Primary. Ovarian Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21061809.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


95. Krusche CA, Vloet AJ, Classen-Linke I, von Rango U, Beier HM, Alfer J: Class I histone deacetylase expression in the human cyclic endometrium and endometrial adenocarcinomas. Hum Reprod; 2007 Nov;22(11):2956-66
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Class I histone deacetylase expression in the human cyclic endometrium and endometrial adenocarcinomas.
  • Recently, HDAC inhibitors were shown to enhance differentiation of endometrial fibroblasts and endometrial adenocarcinomas.
  • However, there is only rare information on HDAC and HAT expression in the human endometrium.
  • In endometrial adenocarcinomas (n = 17), HDAC-1 expression was studied by immunohistochemistry.
  • RESULTS: In the human endometrium, HDAC-1, -2, -3 and PCAF mRNA are expressed without cyclical changes.
  • By immunohistochemistry, nuclear expression of HDAC proteins was detected in all endometrial cell types.
  • In the case of HDAC-3, immunostaining was significantly reduced in the endometrial surface epithelium on day 6-10 (P < 0.01 versus days 15-18 and 24-28).
  • Compared to normal endometrium, a high proportion of endometrial adenocarcinomas showed impaired HDAC-1 protein expression in the epithelial and stromal compartment.
  • CONCLUSIONS: Class I HDACs and HATs are expressed in the human endometrium throughout the menstrual cycle, suggesting the cyclic endometrium as a potential target for HDAC inhibitors.
  • We hypothesis that alterations of HDAC and/or HAT expression are potentially involved in impaired endometrial differentiation.
  • [MeSH-major] Adenocarcinoma / enzymology. Endometrial Neoplasms / enzymology. Endometrium / enzymology. Gene Expression Regulation, Enzymologic. Gene Expression Regulation, Neoplastic
  • [MeSH-minor] Adult. Female. Histone Deacetylase 1. Histone Deacetylase 2. Histone Deacetylases / biosynthesis. Humans. Immunohistochemistry / methods. Middle Aged. Repressor Proteins / biosynthesis. Uterus / enzymology. p300-CBP Transcription Factors / biosynthesis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17728353.001).
  • [ISSN] 0268-1161
  • [Journal-full-title] Human reproduction (Oxford, England)
  • [ISO-abbreviation] Hum. Reprod.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Repressor Proteins; EC 2.3.1.48 / p300-CBP Transcription Factors; EC 2.3.1.48 / p300-CBP-associated factor; EC 3.5.1.98 / HDAC1 protein, human; EC 3.5.1.98 / Histone Deacetylase 1; EC 3.5.1.98 / Histone Deacetylase 2; EC 3.5.1.98 / Histone Deacetylases; EC 3.5.1.98 / histone deacetylase 3
  •  go-up   go-down


96. Bassarak N, Blankenstein T, Brüning A, Dian D, Bergauer F, Friese K, Mylonas I: Is lymphadenectomy a prognostic marker in endometrioid adenocarcinoma of the human endometrium? BMC Cancer; 2010;10:224

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is lymphadenectomy a prognostic marker in endometrioid adenocarcinoma of the human endometrium?
  • BACKGROUND: During surgery for endometrial cancer, a pelvic lymphadenectomy with or without para-aortic lymphadenectomy is performed at least in patients with risk factors (stage I, grading 2 and/or histological subtypes with higher risk of lymphatic spread), and is hence recommended by the International Federation of Obstetrics and Gynecology (FIGO).
  • Although lymph node metastases are important prognostic parameters, it has been contentious whether a pelvic lymph node dissection itself has a prognostic impact in the treatment of endometrial cancer, especially in endometrioid adenocarcinoma.
  • Therefore, this study evaluated whether lymphadenectomy has a prognostic impact in patients with endometrioid adenocarcinoma.
  • METHODS: The benefits of lymphadenectomy were examined in 214 patients with a histological diagnosis of endometrial adenocarcinoma.
  • RESULTS: Of the 214 patients with endometrial adenocarcinoma, 171 (79.9%) were classified as FIGO stage I, 15 (7.0%) FIGO stage II, 21 (9.8%) FIGO stage III and 7 (3.3%) FIGO stage IV.
  • CONCLUSIONS: The performance of an operative lymphadenectomy resulted in better survival of patients with endometrioid adenocarcinoma.
  • Therefore, even in endometrioid adenocarcinoma, a pelvic and/or para-aortic lymphadenectomy should be performed.
  • [MeSH-major] Carcinoma, Endometrioid / surgery. Endometrial Neoplasms / surgery. Lymph Node Excision. Lymph Nodes / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2001 Feb;80(2):139-44 [11161851.001]
  • [Cites] Eur J Cancer. 2009 May;45(7):1304-14 [19231155.001]
  • [Cites] Oncologist. 2003;8(6):541-52 [14657533.001]
  • [Cites] Gynecol Oncol. 2003 Dec;91(3):518-25 [14675670.001]
  • [Cites] CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29 [14974761.001]
  • [Cites] Hum Pathol. 2004 Jun;35(6):649-62 [15188130.001]
  • [Cites] Anticancer Res. 2004 May-Jun;24(3b):2073-8 [15274403.001]
  • [Cites] Cancer. 1987 Oct 15;60(8 Suppl):2035-41 [3652025.001]
  • [Cites] Gynecol Oncol. 1991 Jan;40(1):55-65 [1989916.001]
  • [Cites] Gynecol Oncol. 1995 Jan;56(1):29-33 [7821843.001]
  • [Cites] Am J Obstet Gynecol. 1997 Apr;176(4):777-88; discussion 788-9 [9125601.001]
  • [Cites] J Clin Oncol. 2005 Jun 1;23(16):3668-75 [15738538.001]
  • [Cites] Gynecol Oncol. 2006 Jul;102(1):92-7 [16406063.001]
  • [Cites] Int J Gynaecol Obstet. 2006 Nov;95 Suppl 1:S105-43 [17161155.001]
  • [Cites] Gynecol Oncol. 2007 Apr;105(1):150-6 [17197012.001]
  • [Cites] Eur J Cancer. 2007 Nov;43(16):2434-44 [17911007.001]
  • [Cites] Int J Gynecol Cancer. 2008 Mar-Apr;18(2):255-61 [17624991.001]
  • [Cites] Am J Obstet Gynecol. 2008 Apr;198(4):457.e1-5; discussion 457.e5-6 [18395039.001]
  • [Cites] Acta Obstet Gynecol Scand. 2008;87(12):1361-9 [18951214.001]
  • [Cites] Lancet. 2009 Jan 10;373(9658):125-36 [19070889.001]
  • [Cites] Gynakol Geburtshilfliche Rundsch. 2003 Apr;43(2):104-10 [12649583.001]
  • (PMID = 20492712.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2891635
  •  go-up   go-down


97. Park KJ, Bramlage MP, Ellenson LH, Pirog EC: Immunoprofile of adenocarcinomas of the endometrium, endocervix, and ovary with mucinous differentiation. Appl Immunohistochem Mol Morphol; 2009 Jan;17(1):8-11
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunoprofile of adenocarcinomas of the endometrium, endocervix, and ovary with mucinous differentiation.
  • Primary mucinous tumors of the female genital tract have morphologic features similar to primary gastrointestinal adenocarcinomas, and distinguishing these malignancies may be extremely difficult.
  • The purpose of this study was to characterize the immunostaining patterns of tumors of the female genital tract that show mucinous differentiation using cytokeratin 7 (CK7), CK20, and CDX2 and to evaluate the usefulness of these markers in differentiating these tumors from gastrointestinal tract adenocarcinomas and also from each other.
  • A total of 64 cases were collected, including adenocarcinomas of the ovary (n=13), endocervix (n=16), endometrium (n=34), and vagina (n=1), all of which showed predominant mucinous differentiation.
  • Intestinal mucinous differentiation was present in 11 of the cases (6 endocervical, 4 ovarian, and 1 vaginal adenocarcinoma).
  • However, 25% of endocervical, 24% of ovarian, and 3% of endometrial adenocarcinomas were positive for CDX2, CK20, or both.
  • The positivity for CDX2 and CK20 correlated with intestinal differentiation: 73% of all intestinal mucinous adenocarcinomas and 4% of all Müllerian mucinous adenocarcinomas showed positivity for the hindgut markers.
  • [MeSH-major] Adenocarcinoma / diagnosis. Ovarian Neoplasms / diagnosis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Biomarkers, Tumor / analysis. CDX2 Transcription Factor. Cervix Uteri / pathology. Endometrium / pathology. Female. Homeodomain Proteins / analysis. Humans. Immunophenotyping. Keratin-20 / analysis. Keratin-7 / analysis. Neoplasm Proteins / analysis

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18776815.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDX2 Transcription Factor; 0 / CDX2 protein, human; 0 / Homeodomain Proteins; 0 / Keratin-20; 0 / Keratin-7; 0 / Neoplasm Proteins
  •  go-up   go-down


98. Ma SK, Zhang HT, Sun YC, Wu LY: [Synchronous primary cancers of the endometrium and ovary: review of 43 cases]. Zhonghua Zhong Liu Za Zhi; 2008 Sep;30(9):690-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Synchronous primary cancers of the endometrium and ovary: review of 43 cases].
  • OBJECTIVE: To investigate the clinical and pathological characteristics, treatment methods, and prognosis of synchronous primary cancers of the endometrium and ovary.
  • METHODS: The clinical data of 43 patients with synchronous primary cancers of the endometrium and ovary were retrospectively reviewed.
  • RESULTS: The median age at diagnosis was 49 years (range, 28-73 years).
  • The most common symptoms were abnormal vaginal bleeding (69.8%) and abdominal or pelvic pain (44.2%).Pelvic masses were found in 39.5% of the patients and enlarged corpus in 27.9% at physical examination, while pelvic masses were found in 67.4% of the 43 patients (29 cases) and thickening or abnormal endometrium in 23.3% (10 cases) during ultrasound examination.
  • Of 25 patients examined by CT/MRI, pelvic masses were found in 13 cases and enlarged uterus in 11 cases.
  • All 15 patients who underwent endometrial biopsies were proven to have endometrial carcinomas.
  • FIGO stages of endometrial carcinomas: IA 18 cases, IB 20 cases, IC 2 cases, IIA 3 cases; Stages of ovarian carcinomas: IA 19 cases, IB 4 cases, IC 7 cases, II 4 cases, III C 9 cases.
  • Twenty-four patients (55.8%) were in stage I both endometrial and ovarian carcinomas.
  • Thirty-eight of the 43 patients (88.4%) had a pathologically proven endometrial adenocarcinoma.
  • The predominant ovarian histology was endometrioid or mixed tumor with endometrioid components (30/43, 69.8%).
  • The 3- and 5-year survival rates of patients with both endometrioid and ovarian carcinomas were higher than that of those with non-endometrioid or mixed subtypes (93.8%, 82.0% vs. 79.7%, 69.0%).
  • CONCLUSION: Synchronous primary cancers of the endometrium and ovary are different from either primary endometrial carcinoma or ovarian cancer, while it can usually be detected in early stage and with a good prognosis.
  • [MeSH-major] Carcinoma, Endometrioid. Endometrial Neoplasms. Hysterectomy / methods. Neoplasms, Multiple Primary. Ovarian Neoplasms

  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19173912.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / NBR1 protein, human; 0 / Proteins
  •  go-up   go-down


99. Tantbirojn P, Triratanachat S, Trivijitsilp P, Niruthisard S: Detection of PTEN immunoreactivity in endometrial hyperplasia and adenocarcinoma. J Med Assoc Thai; 2008 Aug;91(8):1161-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of PTEN immunoreactivity in endometrial hyperplasia and adenocarcinoma.
  • OBJECTIVE: To investigate PTEN (phosphatase and tensin homolog deleted on chromosome 10) expression in endometrial hyperplasia and adenocarcinoma as analyzed by immunohistochemistry.
  • MATERIAL AND METHOD: PTEN protein expression was evaluated by immunohistrochemical study of 70 paraffin-embedded curettage endometrial tissue samples (10 normal endometrium, 55 endometrial hyperplasia, and 15 endometrial adenocarcinomas) selected from surgical pathology files of the Division of Gynecologic Pathology, Department of Obstetrics and Gynecology, Faculty of Medicine, Chulalongkorn University, from 2001 to 2004.
  • RESULTS: Absence of PTEN protein expression was detected in 60% of endometrial carcinoma, 60% of atypical endometrial hyperplasia, and 24% of typical endometrial hyperplasia.
  • In endometrial hyperplasia without atypia group, the majority of cases revealed moderate to strong PTEN expression, with 70% in simple hyperplasia and 47% in complex hyperplasia.
  • There is a significant statistical difference of PTEN immunoreactivity among proliferative endometrium, endometrial hyperplasia and endometrial carcinoma group (p = 0.004).
  • CONCLUSION: Complete loss of PTEN protein expression was most commonly found in endometrial carcinoma and hyperplasia with cytologic atypia.
  • [MeSH-major] Chromosomes, Human, Pair 10 / genetics. Endometrial Hyperplasia / pathology. Endometrial Neoplasms / diagnosis. Endometrium / cytology. PTEN Phosphohydrolase / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18788685.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  • [Chemical-registry-number] EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


100. Allhorn S, Böing C, Koch AA, Kimmig R, Gashaw I: TLR3 and TLR4 expression in healthy and diseased human endometrium. Reprod Biol Endocrinol; 2008;6:40
MedlinePlus Health Information. consumer health - Uterine Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TLR3 and TLR4 expression in healthy and diseased human endometrium.
  • TLRs are expressed in the human endometrium and their regulation might be crucial for the pathogenesis of endometrial diseases.
  • METHODS: TLR3 and TLR4 expression was investigated during the menstrual cycle and in postmenopausal endometrium considering peritoneal endometriosis, hyperplasia, and endometrial adenocarcinoma specimens (grade 1 to 3).
  • In addition, TLR4 was present on endometrial dendritic cells, monocytes and macrophages.
  • In patients with peritoneal endometriosis, TLR3 and TLR4 mRNA expression decreased significantly in proliferative diseased endometrium compared to controls.
  • Endometrial hyperplasia and adenocarcinoma revealed significantly reduced receptor levels when compared with postmenopausal controls.
  • The lowest TLR expression levels were determined in poor differentiated carcinoma (grade 3).
  • CONCLUSION: Our data suggest an involvement of TLR3 and TLR4 in endometrial diseases as demonstrated by altered expression levels in endometriosis and endometrial cancer.
  • [MeSH-major] Endometrium / metabolism. Toll-Like Receptor 3 / biosynthesis. Toll-Like Receptor 4 / biosynthesis. Uterine Diseases / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adult. Aged. Endometrial Neoplasms / metabolism. Endometriosis / metabolism. Female. Gene Expression Regulation. Humans. Menstrual Cycle / physiology. Middle Aged. Postmenopause. RNA, Messenger / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 2000 Jan 15;164(2):966-72 [10623846.001]
  • [Cites] Placenta. 2000 Sep;21(7):733-41 [10985978.001]
  • [Cites] Crit Rev Immunol. 2001;21(1-3):179-89 [11642603.001]
  • [Cites] Cell Tissue Res. 2001 Nov;306(2):335-40 [11702245.001]
  • [Cites] Fertil Steril. 2001 Nov;76(5):1012-8 [11704126.001]
  • [Cites] J Immunol. 2002 Jan 15;168(2):554-61 [11777946.001]
  • [Cites] Gynecol Obstet Invest. 2002;53 Suppl 1:19-25 [11834864.001]
  • [Cites] Ann N Y Acad Sci. 2002 Mar;955:101-9; discussion 118, 396-406 [11949939.001]
  • [Cites] Cancer. 2002 Oct 1;95(7):1463-71 [12237915.001]
  • [Cites] Nature. 2002 Dec 19-26;420(6917):860-7 [12490959.001]
  • [Cites] Annu Rev Immunol. 2003;21:335-76 [12524386.001]
  • [Cites] Hum Pathol. 2004 Jan;35(1):47-54 [14745724.001]
  • [Cites] J Biol Chem. 2004 Mar 26;279(13):12542-50 [14729660.001]
  • [Cites] Am J Reprod Immunol. 2004 Jul;52(1):67-73 [15214945.001]
  • [Cites] J Steroid Biochem Mol Biol. 2004 Jun;91(1-2):59-66 [15261308.001]
  • [Cites] Reprod Biol Endocrinol. 2003 Dec 2;1:123 [14651748.001]
  • [Cites] Immunology. 2004 Oct;113(2):153-62 [15379975.001]
  • [Cites] Gynecol Obstet Invest. 2007;63(2):71-97 [17028437.001]
  • [Cites] Gastroenterology. 2007 Mar;132(3):905-12 [17324405.001]
  • [Cites] Hum Reprod. 2007 May;22(5):1373-9 [17234676.001]
  • [Cites] J Reprod Immunol. 2007 Jun;74(1-2):53-60 [17292969.001]
  • [Cites] Immunol Lett. 2007 Jun 15;110(2):139-44 [17532054.001]
  • [Cites] Mol Hum Reprod. 2007 Jul;13(7):503-9 [17483545.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jul 24;104(30):12451-6 [17640886.001]
  • [Cites] Curr Opin Gastroenterol. 2008 Mar;24(2):103-7 [18301257.001]
  • [Cites] Endocrinology. 2008 May;149(5):2261-9 [18202125.001]
  • [Cites] Infect Immun. 2004 Oct;72(10):5799-806 [15385480.001]
  • [Cites] Clin Obstet Gynecol. 1976 Mar;19(1):147-69 [815068.001]
  • [Cites] Lancet. 2004 Nov 13-19;364(9447):1789-99 [15541453.001]
  • [Cites] Int Immunol. 2005 Jan;17(1):1-14 [15585605.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Jan;90(1):548-56 [15509642.001]
  • [Cites] Hum Reprod. 2005 May;20(5):1372-8 [15695310.001]
  • [Cites] Hum Immunol. 2005 May;66(5):469-82 [15935884.001]
  • [Cites] Immunology. 2005 Aug;115(4):565-74 [16011525.001]
  • [Cites] Lancet. 2005 Aug 6-12;366(9484):491-505 [16084259.001]
  • [Cites] Chem Immunol Allergy. 2005;88:150-62 [16129944.001]
  • [Cites] Immunobiology. 2005;210(2-4):153-60 [16164022.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Dec;14(12):2840-7 [16364998.001]
  • [Cites] Endocrinology. 2006 Jan;147(1):562-70 [16223858.001]
  • [Cites] Reprod Biol Endocrinol. 2005;3:74 [16384532.001]
  • [Cites] J Immunol. 2006 May 15;176(10):5805-14 [16670286.001]
  • [Cites] Biol Reprod. 2006 Jun;74(6):1060-6 [16481591.001]
  • [Cites] Proc Am Thorac Soc. 2006 Jul;3(5):401-4 [16799081.001]
  • [Cites] Biol Reprod. 2006 Aug;75(2):176-82 [16672717.001]
  • [Cites] Cell Res. 2006 Aug;16(8):693-701 [16894359.001]
  • [Cites] Shock. 2006 Nov;26(5):430-7 [17047512.001]
  • [Cites] Hum Reprod. 2007 Feb;22(2):586-93 [17043100.001]
  • [Cites] Cancer Res. 2004 Apr 15;64(8):2918-22 [15087412.001]
  • [Cites] J Biol Chem. 2004 Apr 23;279(17):17079-84 [14764599.001]
  • [Cites] Immunology. 2004 Jul;112(3):428-36 [15196211.001]
  • (PMID = 18775079.001).
  • [ISSN] 1477-7827
  • [Journal-full-title] Reproductive biology and endocrinology : RB&E
  • [ISO-abbreviation] Reprod. Biol. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / TLR3 protein, human; 0 / TLR4 protein, human; 0 / Toll-Like Receptor 3; 0 / Toll-Like Receptor 4
  • [Other-IDs] NLM/ PMC2543020
  •  go-up   go-down






Advertisement